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Abstract

Local drug delivery to the inner ear via micropump implants has the potential to be much more effective than oral drug delivery for treating patients with
sensorineural hearing loss and to protect hearing from ototoxic insult due to noise
exposure. Delivering appropriate concentrations of drugs to the necessary cochlear
compartments is of paramount importance; however, directly measuring local drug
concentrations over time throughout the cochlea is not possible. Indirect measurement using otoacoustic emissions and auditory brainstem response are ineffective
as they only provide an estimate of concentration and are susceptible to non-linear
sensitivity effects. Imaging modalities such as MRI with infused gadolinium contrast
agent are limited due to the high spatial resolution requirement for pharmacokinetic
analysis, especially in mice with cochlear length in the micron scale. We develop
an intracochlear pharmacokinetic model using micro-computed tomography imaging of the cochlea during in vivo infusion of a contrast agent at the basal end of
4
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scala tympani through a cochleostomy. This approach requires accurately segmenting the main cochlear compartments: scala tympani (ST), scala media (SM) and
scala vestibuli (SV). Each scan was segmented using 1) atlas-based deformable registration, and 2) V-Net, a encoder-decoder style convolutional neural network. The
segmentation of these cochlear regions enable concentrations to be extracted along
the length of each scala. These spatio-temporal concentration profiles are used to
learn a concentration dependent diffusion coefficient, and transport parameters between the major scalae and to clearance. The pharmacokinetic model results are
comparable to the current state of the art model, and can simulate concentrations
for cases involving different infusion molecules and drug delivery protocols. While
our model shows promising results, to extend the approach to larger animals and to
generate accurate further experimental data, computational constraints, and time
requirements of previous segmentation methods need to be mitigated. To this end,
we extended the V-Net architecture with inclusion of spatial attention. Moreover,
to enable segmentation in hardware restricted environments, we designed a 3D segmentation network using Capsule Networks that can provide improved segmentation
performance along with 90% reduction in trainable parameters. Finally, to demonstrate the effectiveness of these networks, we test them on multiple public datasets.
They are also tested on the cochlea dataset and pharmacokinetic model simulations
will be validated against existing results.
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Chapter 1
Introduction
Imaging of animal anatomy has historically yielded great insight into human biology.
It provides a non-invasive way to measure quantities like tissue density, fluid flow,
and organ development that can translate to improved and novel human medical
applications such as drug development, tissue studies, better medical diagnoses,
and even surgical procedure development. Moreover, in-vivo imaging is employed
to introduce multiple controlled external influences (ex: contrast agents, implants,
surgical devices, etc.) during imaging. This provides scientists with the ability to
carefully design specific experiments to study the anatomy of interest, and design
treatments and procedures related to the anatomy.
We concentrate on one such application of developing and quantifying local drug
delivery mechanisms to the cochlea (inner ear) for patients suffering from sensorineural hearing loss. In this chapter, we present specific disorders affecting the inner ear,
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drug concentration measurement methods, and the use of mouse model as a stepping
stone for developing therapies for human use in the future.

1.1

Cochlear Disorders

Hearing disability can affect 3 out of every 1000 children in United States alone.
Moreover, approximately 15% of adults over the age of 18 can develop some form
of hearing problems [4]. Among various causes for hearing disorder, 90% of the
cases can be attributed to sensorineural hearing loss (SNHL) [5], meaning that
they are related to the inner ear/cochlea or the vestibulocochlear nerve caused by
aging, non-therapeutic level of drugs, and/or exposure to severe noise levels. Fig.1.1
shows the auditory region affected by SNHL. One of the future methods for treating
sensorineural hearing loss involves delivering drugs to the inner ear (cochlea) that can
be effective in restoring complete or partial hearing. Traditional oral drug delivery
methods, or site directed injections are shown to be ineffective in the treatment
of SNHL, due to the blood-cochlear barrier [6, 7]. This inefficacy has led to the
research of local delivery of drugs using cochlear implants [8] that can be deployed
for treatment of acute, as well as chronic hearing disorders.
Emerging inner ear therapeutics for treating sensorineural hearing loss and genetic disorders, and for providing protection, can overcome these limitations by
site-directed delivery of restorative and protective compounds such as prednisone,
dexamethasone [9] via micropumps [8, 10]. These methods can also be used to treat
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Ménière’s disease [11], which is a form of SNHL that is progressive and episodic
in nature. In vision of treating these disorders, inner ear therapeutics and delivery systems have become a major thrust of pharmacokinetics research in the past
decade [12, 13]. Significant work has been done to improve drug delivery methods
[14], with major contribution from intracochlear implants [8, 15]. With application to intracochlear drug delivery, challenges remain with accurately determining
pharmacokinetics (movement of drugs) post-delivery to the inner ear. Specifically,
concentration change of the infused drug in the different fluidic regions of the cochlea

Figure 1.1: Overview of the anatomy of human auditory system with highlighted
cochlear region affected by sensorineural hearing loss. (Image credits: Speech and
Hearing Association [1])
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needs to be studied over time.

1.2

Mouse Model

Large rodents such as guinea pigs, rats, etc. are usually employed by researchers [16]
to develop experiments due to their larger size, which enables easy access to surgical
sites. This is especially true for organs that are in the micron scale or have fluidic
spaces with extremely low volume capacity. In the case of the cochlea, whose volume
capacity can be on the order of nano-liters, researchers have adopted experimenting
on larger rodents since it makes access easier during fluid measurement. However,
the humble mouse is better suited for inner ear studies primarily due to its fully
mapped genome, and the availability of transgenic mice that can closely model
human diseases, thus enabling therapy development in a controlled environment.
In-vivo study of different genes related to auditory function has benefited from
mice bred from transgenic technology. Modeling human diseases and studying gene
functions are some of the research domains enabled by transgenic mice. For example,
transgenic mice were used to study and replicate the mutations in the GJB2 and
GJB6 genes by Schütz et al. [17]. They investigated human bilateral hearing loss in
the mid to high frequency range utilizing the GJB2 and GJB6 genes. These genes
were determined to be the most common cause of prelingual deafness not related to
any syndrome in humans. Moreover, prebycusis, the most common type of SNHL
naturally brought about by the aging of auditory system, can be best modeled in
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inbred mouse strains [18]. This close modeling of genes that cause human deafness
in mice, has enables gene-therapy development for such kind of deafness. It can thus
be argued that transgenic mice with specific mutations is a better animal model for
in-vivo studies than larger rodents like guinea pigs or chinchilla.
The size of the mouse model does indeed pose a few challenges, especially in
studying inner ear drug delivery. The fluid capacity (perilymph) of the mouse
cochlea is approximately 620 nL [19]. This is dwarfed by the capacity of the human
cochlea which is orders of magnitude larger at 150-200 µL [20]. This small size of
the murine cochlea makes precise surgical procedures required for inserting fluidic
interfaces highly challenging [21]. Moreover, the small volume capacity restricts extended high flow rate experiments [22], which can lead to leakage at the surgical
site, or in worst case, rupture of the cochlea.

1.3

Concentration Measurement

Measurement of drug concentration within the cochlea can be broadly classified into
direct and indirect methods, which are both described in this section.

1.3.1

Direct Methods

Direct methods for measuring drug concentrations are based on measuring a specific
ion (e.g.: trimethylphenylammonium) using ion-selective micro-electrodes [23], or by
drawing minute perilymph samples from the basal [24, 25] or apical turns [26, 27] of
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the cochlea or from the vestibular canals [28, 29]. These methods are limited in their
spatio-temporal resolution and are difficult to employ in animals smaller than the
guinea pig. Perilymph sampling might result in cerebral spinal fluid (CSF) contaminating the samples [27, 25], complicating interpretation of the concentration results.
There remains a need for advanced methods to monitor drug concentrations within
the three cochlear scalae over time that provide enhanced spatial resolution and are
suitable for a broad range of infused compounds and animal species, including the
genetically-mapped murine model system.

1.3.2

Indirect Methods

Indirect measurement methods can preserve the structural integrity of the inner
ear and help obtain spatio-temporal concentration profiles within the cochlea without the issues faced with invasive measurements and fluid sampling. One way of
performing indirect measurement is through functional assessment methods like distortion product otoacoustic emissions (DPOAE) [30, 31] and auditory brainstem
response (ABR) [32, 33] that estimate concentration within the cochlea based on
the physiological response of cochlear hair cells or spiral ganglion neurons to a delivered ototoxic agent [34]. In this approach, a physiological place-frequency map
of the cochlea is used to correlate auditory responses with cochleotopic position
[30]. However, these methods only provide an indirect estimate of concentration,
and accuracy may be impacted by non-linear sensitivity effects. Magnetic resonance
imaging (MRI) has been used for qualitative [35] and semi-quantitative [36, 37, 38]
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assessment of gadolinium distribution within the cochlea following transtympanic
injection in humans and application to the round window membrane niche in guinea
pigs. However, resolution limitations (1.5 to 2 mm) preclude use of MRI for high
fidelity pharmacokinetic analysis, especially in smaller rodents such as the mouse
with total cochlear length less than 7mm. In contrast, µCT provides sufficient spatial resolution with direct measurement of concentration of an infused Iodine-based
contrast agent within all cochlear compartments, enabling quantification of local
drug delivery at micron resolution.

1.4

Pharmacokinetics

In order to enable intracochlear analysis of fluid flow in mice via high resolution
imagery, the use of contrast-enhanced µCT was first introduced by Haghpanahi and
colleagues [39] wherein they processed and analyzed the scans in 2D, slice by slice.
The 2D method required selecting key slices that were further processed. This meant
that the concentration of the contrast agent was obtained only in those key slices,
and failed to leverage the spatial resolution provided by µCT. Concentrations were
extracted at 5 locations along ST and scala vestibuli (SV) at four time points spread
across a 90-minute infusion [39] demonstrating the potential for direct, non-invasive
assessment of intracochlear concentrations of a delivered drug.
In the present work, we extend this high-resolution technique with 3-D image
registration and segmentation enabling high spatio-temporal resolution interroga-
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tion of all three major cochlear compartments in the mouse: ST, SV, and scala
media (SM). By capturing a series of six µCT scans over 170 minutes before and
during infusion of a contrast agent into the murine cochlea, we measured the spatial
concentration profiles through each of the scalae in each scan, and then assembled
these profiles to generate spatio-temporal concentration profiles. These extracted
concentration profiles are used in our pharmacokinetic model of inner ear to learn
transport parameters along scala, between scalae, and to clearance. The model is
designed considering the scala as compartments, and flow between these compartments is modeled using differential equations. Once these parameters are learnt, we
can simulate the concentration profiles for multiple infusion initial conditions and
different solute compounds.
To address all these issues and novel ideas, in this thesis, we design a system that
extends the process to 3D [40], so that concentration could be extracted at every
spatial point along the scala. The system shown in Fig. 1.2 consists of the following
steps: 1) Micro CT imaging system with the surgical procedures improved based on
feedback from previously collected images. 2) 3D atlas-based registration OR convolutional neural networks for segmenting the cochlea into ST, SM and SV scalae. 3)
Extract the concentration of the contrast agent within these scalae. 4) Pharmacokinetic model which simulates the concentration given a set of transport parameters
that describe transport within and across the scalae. These parameters are learnt
through a gradient descent algorithm that uses the extracted concentrations as the
reference.
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Figure 1.2: Flowchart of our system starting from micro CT imaging, followed by
segmentation of scalae into ST, SM and SV. The segments are used to extract the
concentration within the cochlea. These extracted concentrations are then used by
the pharmacokinetic model to estimate transport parameters.
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1.5

Novel Contributions

This section presents a summary of the novel contributions of this work.

1.5.1

Chapter 3

• Novel 3D pipeline to indirectly and noninvasively measure contrast agent concentration in infused cochlea using µCT imaging.

• Atlas based 3D registration and segmentation of the scala tympani (ST), scala
media (SM), and scala vestibuli (SV) for contrast agent concentration extraction. This contribution was an improvement from the previous 2D based registration and segmentation which involved manual handpicking of individual
2D slices from both the scans, as well as the atlas, and verifying that the slices
matched. Current method performs the registration in 3D enabling extraction
of concentration without the loss of spatial resolution.

• Skeletonization of segments to obtain the medial axis, and its reparameterization using splines to obtain a plane normal to the axis of each scala along
which concentration is extracted. This method ensures that the concentration
is extracted around the center of the scala, eliminating any bone to be included
in the extracted concentrations.
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Chapter 4

• First dataset to explore segmentation of cochlear structures using Convolutional Neural Networks.
• Improved performance of V-Net using consecutively increasing dilated convolutions. Dilated convolutions provide better performance than regular convolutions due to their ability to look at a larger part of the image as a result of
increased receptive field. Having dilated convolutions early on in the network,
enables the network to learn better features from the get go.

1.5.3

Chapter 5

• New pharmacokinetic model to simulate fluid concentration within ST, SM
and SV. Previous models were developed using invasive methods to extract
concentrations, making them less scalable. Moreover, the measurements of
the cross-sectional area of the compartments had to be manually measured.
Our model utilizes only the micro CT images to extract concentrations, as
well as measure the areas required to build the model. This makes the model
highly scalable to larger rodents, as well as larger number of experiments.
• Concentration based diffusion coefficient at every spatial point within the scalae.
Instead of having a single diffusion coefficient throughout the scala, we have
proposed and used a concentration dependent diffusion coefficient that can
change at every point along the length of the scala based on the concentration
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at that point. This was observed in our experiments as well. Concentration
based diffusion coefficient is a new concept introduced as part of our pharmacokinetic model that is not seen in existing models like FluidSim.
• Learning-Prediction model to optimize transfer coefficients. We implement a
gradient descent algorithm for faster convergence on the transfer coefficients.
• Pulsatile Delivery: simulating chronic drug delivery applications of micropump
implant using our pharmacokinetic model.

1.5.4

Chapter 6

• Applied attention gating module to V-Net and showed performance improvement on Cochlea dataset. Attention gating module was extended to the V-Net
from the standard U-Net it was designed on.
• Extended the locally constrained dynamic routing algorithm to work on 3D
networks.
• Implemented V-Net like residual connection in 3D-SegCaps and showed improved performance on LUNA dataset. Residual connections have been proven
to improve performance in V-Nets. We extend the concept to capsule networks
for segmentation and achieve better accuracy.
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Chapter 2
Imaging The Cochlea
This chapter discusses the imaging procedures and modalities used in this work.
Specifically, it presents the use of Micro Computed Tomography (µCT) and its
application to cochlear imaging. Finally, it explains the mouse surgery details prior
to imaging, and µCT pre-processing are explained along with a calibration step
needed to translate voxel intensity values to physical units.

2.1
2.1.1

µCT Imaging
Computed Tomography (CT) Imaging

CT works by combining multiple X-ray measurements taken from multiple angles,
usually in a cylinder, sphere, or helix around the object. The fundamental principle here is that the measurements are directly proportional to the density of the
39
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material the x-ray beams pass through. During CT reconstruction, the attenuation coefficients are calculated (also known as line integrals) using Radon transform
at every angle. These coefficients are then transformed to a linear scale known as
Hounsfield scale in which the radiodensity of distilled water at standard temperature and pressure (STP) is defined to be 0 Hounsfield units (HU). The transformed
values are then combined to obtain a volume consisting of slices (tomograms) in
each of the three orthogonal dimensions [41]. µCT is similar to the CT scanners
used in medical facilities, but the scale of objects imaged is smaller than 125-165
mm [42, 43], and the resolution of the scans can be as small as 100 nanometers [43]
in each dimension. Specifically to imaging animals, µCT has been used successfully
to scan bone regions for arthritis in rats[44], vascular structures in kidneys [45] and
livers [46] in rodents from the past 20 years [47]. However, one of the major disadvantages of using CT is the inherently poor contrast of soft-tissues. This is overcome
by using contrast agents to discern different anatomical features in vivo. Majority
of animal imaging soft tissue imaging (organ or vasculature imaging) involves using nanoparticles [48, 49], or non-ionic organoiodine based [50, 51] contrast agent
to differentiate the tissue, or vasculature under consideration from the surrounding
anatomical regions. Moreover, delivery of a contrast agent with a high attenuation
coefficient relative to the tissues surrounding it enables direct visualization of the
contrast agent concentration within the imaged 3D space.
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Cochlea µCT - Previous Work

Haghpanahi et al. infused an organoiodine radiographic contrast agent in vivo into
the mouse scala tympani (ST) via cochleostomy (an opening in the cochlea) during
live animal µCT scanning [39]. By establishing a calibrated relation between image
intensity in and contrast agent concentration, the intracochlear concentrations can
be non-invasively quantified in the major compartments of the cochlea. To identify
fine membrane features that delineate the cochlear compartments, Haghpanahi et
al. performed a two-dimensional (2D) image registration of selected slices to a
murine cochlear atlas [2] and passed segmentation or labeling information from the
atlas to the µCT scan. Concentrations were extracted at five locations along ST
and scala vestibuli (SV) at four time points spread across a 90-minute infusion
[39] demonstrating the potential for direct, non-invasive assessment of intracochlear
concentrations of a delivered drug.
We extend this high-resolution technique with 3D atlas-based image registration
and segmentation enabling high spatio-temporal resolution interrogation of all three
major cochlear compartments in the mouse: Scala Tympani (ST), Scala Vestibuli
(SV), and scala media (SM). To the best of our knowledge, this is the first work done
on cochlear µCT imaging with infused contrast agent. Among the various contrast
agents, we mainly infused organoiodine contrast agent (Iopamidol) in majority of
our scans. Moreover, to test the effect of other contrast agents, experiments were
conducted with gold nanoparticles (15nm diameter). By capturing a series of six
µCT scans over 170 minutes before and during infusion of a contrast agent into the
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murine cochlea, we measured the spatial concentration profiles through each of the
scalae in each scan, and then assembled these profiles to generate spatio-temporal
concentration profiles. Furthermore, we utilize these concentration profiles to create
a learning-prediction (LP) model of inner ear pharmacokinetics to learn transport
parameters along scala, between scalae, and to clearance.

2.2

µCT of Cochlea

We setup similar surgery and imaging procedures as initially followed by Haghpanahi
et al. [39], as described in this section.

2.2.1

Surgery and Infusion Procedure

Young adult CBA/CaJ mice (age: 3-6 months) were used in all our experiments. All
animal procedures were approved by the University of South Florida Institutional
Animal Care and Use Committee and were performed using National Institutes of
Health and veterinary standards of care [52]. Following the procedures originally
detailed in Borkholder, et al. [30], animals were anesthetized (ketamine/xylazine)
and the left ventral surface of the neck was cleaned to prepare for surgery. Surgery
was performed on the left ear of the mice. A cochleostomy was drilled at the base of
ST near the round window. Infusion tubing was inserted into the cochleostomy using
a micromanipulator (MM3-3, World Precision Instruments, Sarasota, FL) and the
cochleostomy site was sealed permanently using dental cement (3M ESPE Durelon,
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Figure 2.1: Setup for drug delivery to the mouse cochlea. A volume of 5000 nl of
Iopamidol (Isovue) is delivered. The air bubbles between the volumes of Artificial
Perilymph (AP) and Iopamidol prevent their mixing and also provide a visual reference to ensure the rate of flow through the tube. The holder, functionally the same
as shown above, has three points of contact with the mouse to ensure the head stays
in the required position throughout the experiment.

St. Paul, MN) and super glue. The surgery site was loosely sutured closed to provide
strain relief for the infusion tubing. The mouse was placed in a 3-D printed custom
holder to help maintain a steady head position during transport to the scanner
and during imaging, and to provide precise placement of the isoflurane (anesthesia)
delivery system during the entire scanning process. Proper positioning of the head
during scanning fixes the orientation of the cochlea in the scanner, and minimizes
motion artifacts that can cause errors in subsequent image processing steps. The
animal’s heart rate and respiration were monitored throughout the experiment to
maintain the proper levels of general anesthesia done via continuous flow of 1.5%
isoflurane during scanning.
ISOVUE® -370 containing 755mg/ml of Iopamidol which equates to 370mg/ml
organically bound iodine (Bracco Diagnostics) was diluted to 240mg/ml organically
bound iodine with artificial perilymph (AP). A 30 - 40 cm length of US Pharma-
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copoeia Class VI polyimide tubing (044-I; ID 110 µm; OD, 139 µm; Microlumen,
Tampa, FL) was connected to a 25 µl Hamilton syringe (1702 RNR 22S/2”) that
was mounted to the pump (Standard Infuse/Withdraw PHD ULTRATM Syringe
Pumps ( Cat No.: 70-3005); Harvard Apparatus, Holliston, Massachusetts) allowing
accurate infusion rate control. The syringe was carefully filled with 1000 nl AP, 5000
nl of 240 mg/ml Iopamidol solution, and 1000 nl AP, each separated by a 10 nl air
bubble to avoid diffusion between fluids as shown in Fig. 2.1. The syringe pump was
powered from an inverter running on a 12 V battery to permit continuous infusion
during surgery and transport to the µCT scanner. Flow was set to 16 nl/min to
provide continuous AP flow during surgery, transport to the scanner, and the initial
baseline scan (no contrast agent). Following the baseline scan, the flow rate was
changed to 32 nl/min and the second scan was started to coincide with initiation of
delivery of contrast agent. Scans continued serially for 140 additional minutes with
continuous infusion of contrast agent to the basal turn of ST via cochleostomy.
A total of 4800 nl of the contrast agent was infused into the cochlea during each
experiment at a rate of 32 nl/min for 140 min. While the total perilymph volume
of ST and SV of the mouse is only about 620 nl [19], the patent cochlear aqueduct
(CA) provides a fluidic exit where infused agent exits ST and flows into the large
cranial subarachnoid space. As shown in Fig. 2.2, the CA is positioned basal to
the cochleostomy (CO), providing a region of high concentration of infused agent
at the base, with diffusion mediated transport to more apical regions and to other
scalae and clearance. Within the scalae, diffusion is characterized by a concentration
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Figure 2.2: Theoretical flow path within the cochlea for a ST cochleostomy (CO)
infusion. Pressure driven flow is depicted with solid lines while diffusion is depicted
with dotted lines. The infusion results in advective flow through the cochlear aqueduct (CA) and diffusion-mediated transport through the cochlear spaces. Transport
between scalae and to clearance that are modeled for the murine system are depicted
as K values.

dependent diffusion coefficient (D), whereas inter-scalae transport and clearance are
defined by transport parameters (K). These parameters are explained in detail in
the pharmacokinetics modeling section.

2.2.2

Imaging and Infusion Details

Imaging was performed on a Siemens Inveon PET/CT scanner with scan parameters
as shown in Table 2.1. Reconstruction was done using ordered subset expectation
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Table 2.1: Siemens Inveon PET/CT scanner parameters used in our experiments
Parameter
Value
Cone Beam Voltage
80 kVp
Cone Beam Current
500 µA
Exposure Time per Projection
3000 ms
Scan Arc
180 ◦
Number of Projections
360
Voxel Resolution
16.38 µm isotropic

Units
kilovoltage Peak
micro Ampere
milli seconds
degree
-NAmicro meter

maximization (OSEM) with beam hardening correction. Whole head images were
1024×1024×512 voxels with an isotropic resolution of 16.38×16.38×16.38 µm. The
mouse holder was placed inside the µCT scanner and a low resolution scout view
was obtained to accurately position the scan window in the region of the ipsilateral
cochlea. Scans were obtained continuously for ∼170 minutes with infusion of AP
for the first ∼30 minutes or until the 1000 nl AP was delivered. Contrast agent was
delivered for the remaining 140 minutes. Each experiment consisted of 1 baseline
scan and 5 contrast agent infusion scans (5 time points) with each scan captured
over 20 minutes with a wait time of 10 minutes. The baseline scan is imaged with
only the AP infused and no contrast agent to enable robust image registration,
and to provide a zero concentration baseline throughout the cochlear scalae for
quantitative assessment of contrast agent intensity. The contrast agent volume was
recorded from the syringe pump and was visually verified by movement of the 10 nl
air bubble between the contrast agent and trailing AP solution.
The cochleostomy experiments were carried out on a total of 17 animals and
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were used to test the 3-D image registration algorithms. Of the 17 animals, three
were used for final contrast agent infusion for purposes of quantitative pharmacokinetic model development and learning of diffusion and transport parameters. These
specific experiments achieved minimal or no leakage at the cochleostomy site with
expected rapid increases in basal contrast agent concentration.

2.3

Image Pre-processing

After the scans are obtained post-surgery, they are converted to the required medical
image format and orientation (if required), followed by the extraction the cochlea
from the full head scan. A calibration scan is also imaged using the same machine,
so that a linear relationship between the contrast agent concentration values in
Hounsfield units (HU) and physical units in mg/ml can be established.

2.3.1

Cochlea Extraction

Images of the entire head of each mouse are natively obtained in DICOM format
(Digital Imaging and Communications in Medicine [53]), with each slice being an
individual image. Since the atlas and the scans are in different formats, the conversion to NIFTI achieves a uniform format for further processing steps. To identify the
cochlear region within the whole head scan, we visually identify the basal and apical
turns of the cochlea, localizing a region of interest (ROI) with 15 to 25 voxel buffer
space (240 - 400 µm) around the ipsilateral cochlea to accommodate for motion
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caused by breathing of the animal. However, for scans with significant motion artifacts, the ROI needs to be selected individually for each of the 6 scans. This is done
using ITK-SNAP software [54], which enables manual selection of the starting points
and size of the cuboid ROI. Even though the ROI selection process potentially can
be automated by looking for the geometric features of the cochlea, we noticed that
some features become ambiguous after infusion of contrast agent. Manual extraction
in such cases is more time efficient and also provides accurate ROI adjustment for
motion artifacts caused by animal’s respiration. In order to match the resolution of
the atlas with that of the µCT scans, we resample the atlas and the label maps to
have isotropic 16.38 × 16.38 × 16.38 µm resolution. The atlas image is resampled
by linear interpolation, and the label maps are resampled by nearest-neighbor interpolation. The atlas is chosen over the µCT scans for resampling due to its higher
resolution, and to avoid introducing artifacts into the µCT scans that can alter the
contrast agent concentrations to be extracted.

2.3.2

µCT Calibration for Contrast Agent Concentration

The values associated with voxels in a µCT scan are in Hounsfield units (HU), which
is a linearly transformed version of linear attenuation coefficients, shifted and scaled
so that the radiodensities of distilled water and air at standard temperature and
pressure are defined to be 0 HU and -1000 HU, respectively. To transform from HU
to units of concentration (mg/ml), we carried out a calibration procedure similar to
that defined in [39]. We placed seven pipet tips filled with contrast agents at 50,
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concentration in mg/ml with sensitivity cutoff marked by
Bottom: Linear fit between HU and Concentration values

100, 150, 200, 240, 370 (mg/ml) Iopamidol in a custom 3-D printed holder along
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with a pipet tip filled with saline (reference solution for 0 mg/ml). These are then
imaged in the same µCT scanner using settings identical to those used during the
animal experiments. After the images are obtained, the procedure to fit the HU
values to the concentration in mg/ml, and finding sensitivity cutoff is carried out
as follows. The average HU value for the entire volume of each pipet are plotted
against the respective Iopamidol concentrations, and a linear curve is fit to the data
points as shown in Fig. 2.3.
This provides us with the slope of the line that is used to obtain an equation for
the conversion. An R2 value of 0.9968 (coefficient of determination) is obtained, indicating a strong linear fit between HU values and concentration, with the conversion
defined by C = (HU +53.1569)/29.4133 where C is the contrast agent concentration
in mg/ml and HU are Hounsfield units from the µCT scan. A sensitivity cutoff of
2.655 mg/ml was obtained using the ratio of standard deviation of HU values of
each pipet to the previously calculated average concentration values ( σCC ). These
ratios were plotted against ioversol concentration and a power curve (axb ) was fit
to these points. The concentration at which the point on the curve equalled a ratio
of 1, was defined as the sensitivity cutoff. The sensitivity cutoff is the value below
which Iopamidol concentrations cannot be resolved above the noise. The average
of concentrations taken in a circular window in the calibration scans with diameters ranging from 1 to 15 showed that the variation in concentration decreased
below the sensitivity cutoff value when a 7 diameter or above circular window was
chosen. This averaging window is later used to extract concentration from the scala.
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The next step in the image processing pipeline is to prepare the atlas, perform
registration and segmentation, and finally extract the concentration.
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Chapter 3

Atlas-Based Segmentation and
Concentration Extraction

The main challenge of extracting concentration from each compartment in the
cochlea is to accurately identify these compartments in the µCT scans. Manual
segmentation of each of these compartments in every 3D scan can be accurate, but
the amount of effort required for manual segmentation does not enable scaling this
approach to handle multiple scans.
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Atlas-Based Segmentation and Concentration Extraction

3.1

Medical Image Segmentation: Literature Review

Anatomical region localization is a key step in medical image analysis. The aim
of segmentation is to extract all organs of interest and then pick the one which is
required for the analysis. Techniques used for medical image segmentation can be
broadly classified into:
• Region based segmentation - a set of seed pixels initialized inside the region to
be segmented is grown outwards till it covers the boundary of the region [55].
A segment can consist of multiple such regions that are later merged based on
some criterion to form a single segment. These methods perform well when a
clear region boundary is visible.
• Clustering based segmentation - this is an unsupervised method of segmentation where ’K’ clusters are formed based on similar pixel spectral properties.
This methods works well in segmentation of brain MRI where the soft-tissue
within the skull can have similar pixel intensities based of T1 or T2 weighting [56]. Choosing the value of ’K’ can be non-trivial and a drawback of this
method since the value of ’K’ varies depending on the problem statement.
• Segmentation using neural networks - these can unsupervised or supervised
method of segmentation. However, most state of the art techniques popularly
used for research are supervised, and are based on convolutional neural net-
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works. U-Net [57] is one such convolutional neural network architecture that
is widely used in medical image segmentation. The need for large datasets
with labeled segmentation data can prove disadvantageous in some medical
imaging applications.

• Atlas based segmentation - in cases where labeled data is not available and/or
region boundaries between different anatomies are not clearly visible, a template is made use of known as the atlas. The atlas can be a single image or
a statistical combination of multiple images. The advantage of having such
an atlas is that the segments in the atlas are pre-labeled. This atlas is then
registered to the image at hand, and upon successful registration, the image
is segmented by resampling the labels of the atlas to the image using the
registration parameters.

The effectiveness of the segmentation influences the accuracy and reliability of
subsequent results during the analysis stage. In this work, the µCT imaging does not
capture the soft-tissue membranes between different compartments in the cochlea.
This can be problematic even for expert labelers to manually segment the compartments. Due to absence of labeled data for the cochlea images, we adopt atlas
based segmentation initially and later as labeled data is created, use state of the art
convolutional neural networks.
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3.1.1

Rigid and Affine Registration

In atlas based segmentation, the segmentation problem is solved by performing
image registration. Simple registration techniques involving rigid transforms and
affine transforms can offer faster optimization with reasonable accuracy, whereas
more complex deformable models do a better job at obtaining a more accurate
registration while compromising on computational time.
Generally, any registration technique involves a moving image (atlas) and a fixed
image (image in consideration). Feldmar et al. [58] introduce a local affine transformation method that looks for minima in the surface under consideration and
produces a smooth transform. Kalman filters are used to ensure the optimizer converges. Following the work of Feldmar et al.[58], Jenkinson et al. [59] apply a fast
local optimization (Powell’s method [60]) combined with an initial search phase to
give robust global affine transformation. The cost function for their optimization
is either the correlation ratio or mutual information, and trilinear interpolation is
performed to evaluate the moving image at each voxel position in the fixed image.
The optimization is done over multiple resolutions. Butz et al. [61] generalize the
mutual information (MI) metric over any feature space. They introduce a quantity
called the edgeness measure, which does not tell whether a voxel is an edge or not.
The MI registration using this gradient feature space exhibits better accuracy in
comparison to intensity based MI registration.
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Deformable Registration

Even though affine transformation is a non-rigid transformation, it does not capture
all the non-linearity in the structure of an image. The term deformable defines
the fact that the atlas is associated to the fixed image through non-linear dense
transformations. The selection of the deformation model is dependent on the need
for computational efficiency vs. accuracy of description.

Davis et al. [62] introduced a physics based Elastic Body Splines (EBS). They
use the Navier-Cauchy equilibrium equations for a homogeneous isotropic elastic
body subjected to forces and find its solutions to get the splines. To solve these
analytically, the force is derived from the landmark correspondences between fixed
and moving images. Extending this, Kohlrausch et al. [63] model the forces as a
Gaussian function of distance from the landmark in the images. This results in the
model being resilient to local deformations.

A type of free form deformation called B-splines was introduced to perform
image registration by Rueckert et al. [64]. This technique uses normalized mutual
information as the voxel based similarity metric, making the algorithm insensitive
to contrast changes in the image. This also models the local deformations which
can vary from image to image, thus giving an overall smooth transformation.
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Figure 3.1: Overview of the preprocessing and registration stages - Given the original
DICOM images, the region of interest (ROI) for the infused cochlea is extracted
from each scan and stored in NIFTI format. Similarity and Affine registration are
performed between the atlas and the extracted image of the cochlea, followed by a 3D deformable B-spline registration. The affine registration provides a good starting
point for the B-spline registration. The segments are then separated into ST, SV,
SM and SL, and because the SL is only 2 to 6 voxels thick (32 to 96 µm), it is
omitted from further processing. Given the segmented regions, the medial axis is
calculated and re-parameterized in terms of arclength. Intensities (Hounsfield units)
from 7 voxel diameter discs are averaged at every 1% point along the medical axis
for each scalae in each scan. Intensities are converted to concentration (mg/ml)
based on a pre-determined calibration curve.

3.2

Cochlear Registration and Segmentation

A overview of our processing pipeline from registration and segmentation, to concentration extraction is show in the Fig. 3.1. Individual steps are explained in the
consecutive sections below.
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Figure 3.2: Atlas image stacks are provided in TIFF format [2] with different regions
marked in RGB format color contours as shown in A. Specifically, we extract : ST
[R-156, G-0, B-0], SM [R-235, G-228, B-121], and SV [R-126, G-126, B-255] from
the contours to obtain 2D label map slices as seen in B. The 3D atlas is constructed
from these images, and the label maps of ST, SM and SV are converted to the
corresponding 3D versions as shown in the 3D rendering in C. Apart from the label
maps shown above, we also extract the basilar membrane and spiral ligament which
are used to obtain the contact areas between ST-SM and SM-clearance, respectively.

3.2.1

Mouse Cochlear Atlas

Estimating pharmacokinetic model parameters requires obtaining spatio-temporal
profiles of the contrast agent concentrations in the three main scalae (ST, SM and
SV). However, the scalae are not easily identified in the µCT scans of the cochlea
since fine membranes provide insufficient image contrast for visualization. In order
to differentiate them, a template (atlas) of the mouse cochlea with various preidentified regions published by Santi, et al. [2] was used. The atlas was obtained
from OPFOS (Orthogonal-Plane Fluorescence Optical Sectioning Microscopy) images of the decalcified cochlea of a CBA mouse. The individual region boundaries
including ST, SM, SV, CA, SL, basilar membrane (BM), and organ of Corti (OC)
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are segmented in these images by an expert human observer based on the definition
and visual recognition of the tissue borders. The image stacks are provided with
metadata in TIFF format as part of the atlas, along with outlines of all the segmented regions. The color-coded segmented regions (colored outlines) of the main
cochlear compartments and structures are extracted and converted into individual
2-D label maps. The label maps and the image stacks are converted to NIFTI (Neuroimaging Informatics Technology Initiative [65]) format to form individual 3D label
maps as shown in Fig. 3.2, and a 3D atlas, each having 5.43µm ×5.435µm ×20µm
non-isotropic resolution.

3.2.2

3D Registration and Segmentation

To solve the problem of segmenting the three major scalae in the cochlea, an atlas
based registration approach is implemented in C++ using the Insight Toolkit library
[66]. In this approach, the cochlear atlas is geometrically transformed using a cascade of transformations so that it optimally aligns with the ROI extracted from the
current µCT baseline scan. In general, registration algorithms find a transformation
τ , such that the transformed moving image Im (the atlas) is spatially similar to the
fixed image If (µCT). These algorithms require defining (i) a class T of valid geometric transformations from which τ can be drawn, (ii) a cost function F (Im (τ ) , If )
that measures the dissimilarity between the transformed moving image Im (τ ) and
the fixed image If , and (iii) an optimization procedure for minimizing the cost function over the class of valid geometric transformations. Given these components as
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Figure 3.3: Illustration of the registration process which takes a fixed (µCT) and
moving (atlas) image as input, and calculates a metric (cost function) between
them to optimize the transformation. The optimizer stores the final transformation
parameters that are used by the moving interpolator to fill in values at non-voxel
locations. Fixed transform, fixed interpolator and virtual image are temporary
intermediate stages created to help with optional pre-transformation, interpolation
necessary for pre-transformation, and to carry out computations in a physical grid
apart from the fixed image respectively.

seen in Fig. 3.3, registration can be thought of as solving the following minimization
problem:

τ̂ :=τ ∈T F (Im (τ ) , If )

(3.1)

We consider three different classes of geometric transformations: similarity transformations, affine transformations, and B-spline free-form deformations. Similarity
transformations [67] allow arbitrary translations, rotations, and isotropic scaling of
the moving image. Affine transformations [68] allow translations, rotations, different scaling along each dimension, and shear factors between pairs of dimensions.
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B-spline free-form deformations [64] enable smooth local changes in the moving image and are parameterized by a grid of control points that are allowed to undergo
independent displacements. These transformations are successive subsets of one
another, and they have increasing complexity. In three dimensions, similarity transformations have seven parameters, affine transformations have twelve, and B-spline
free-form deformations have M × M × M parameters, where M is the number of
control points in each dimension (uniform grid). Since the solutions to registration
using simpler transformations can be used to provide initial estimates for registration using more complicated transformations, we progressively perform registration
using each of these three geometric transformations, as shown in Fig. 3.2. Combining the results of all the three stages allows us to write the final transformation τ̂ as
the composition of the transformations found from similarity, affine, and B-spline
based registration:

τ̂ = (τ̂B−spline (τ̂af f ine (τ̂similarity )))

(3.2)

For the cost function, we employ the negative correlation coefficient between the
image data; i.e.

PN
F (Im (τ ), If ) = − r

i=1 (If i .Imi (τ ))

PN

2
i=1 If i

 P

N
i=1

2

(Imi (τ ))

,

(3.3)

where If i is the ith voxel of fixed image, Imi is the ith voxel of moving image,
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and N is the number of voxels in the region of overlap between and Im and If .
Simpler cost functions for single modality registration, such as the sum of squared
differences or sum of absolute differences, may have difficulties in regions of high
concentration of the contrast agent. More complicated cost functions for multiple
modality registration, such as mutual information or normalized mutual information,
do not explicitly account for the correlations in the moving and fixed images that
occur in this application.
For the optimization procedure, we use Regular Step Gradient Descent (RSGD)
[69] for minimizing the cost function with respect to each class of geometric transformation. RSGD is based on gradient descent but incorporates an extra initial
hyperparameter known as the relaxation factor. The relaxation factor decreases the
step lengths of the transformation parameters (the amount of change in each iteration) every time a gradient change occurs in the direction of the minima. We define
the criterion for terminating the optimization procedure to be when the step length
between two consequent iterations is less than or equal to 10−6 .
Using this final transformation τ̂ , the label maps are transferred into the geometry of the µCT scans. Although we restrict our analysis to the three main scalae
and SL, τ̂ can be applied to any number of regions that exist in the atlas. Finally, to
account for minor motion artifacts in subsequent scans, we apply a transformation
to the B-spline transformation result, identical to similarity transformation, but restrict it to only rigid translations, simulating movements that might be caused by
animal respiration.
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3.2.3

Concentration Extraction

Given the segmented volumetric representations of the scalae (label maps), the medial axis for each scala is extracted using morphological thinning [70, 71] followed
by pruning (removing unwanted branches of the medial axis) [72]. Morphological
thinning relies on the concept of connected components, where every voxel in the
label map is considered to be connected to every other voxels in 3-D by 26 connections (3 × 3 × 3 grid). When the voxel is at the surface of the label map, it will have
fewer than 26 connections. Such surface voxels are removed iteratively towards the
center of the label map, retaining the end point voxels. This is repeated until all the
surface points are removed, thinning it in the process until only a 1-2 voxel thick
axis is left. Due to the uneven nature of anatomical volumes, the thinning might
assume multiple end points and create erroneous random branches from the central
axis that need to be pruned. This pruning is done by manually fixing the start
and end point of the medial axis, and iteratively eliminating any terminating point
which is not part of the medial axis. The start point (zero point) is visually selected
to be the bifurcation point of the round window membrane concave region in ST.
For SV, a bifurcation is seen in the medial axis at the region where the vestibule
starts, which is picked as the start point. A plane normal to the tangent at the start
point for SV, cuts the SM medial axis, which is picked as the zero point in SM. The
ending points of all three scalae are chosen to be the final point at the apex in the
medial axis that can be visually discerned.
The final medial axis as seen in Fig. 3.4 is defined in terms of a discrete set of
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Figure 3.4: Example of medial axis extraction from an ST label map. A is the
label map obtained from the registration and segmentation process. B is the label
map after morphological thinning is applied. The thinned label map still contains
stray branches (red arrow) off of the medial axis that are removed in the subsequent
pruning process, which yields the right-most label map. It can be observed that the
round window membrane (RWM) branches are missing from the final medial axis
owing to the fact that we consider zero-point of ST for concentration extraction after
the round window branch, near the cochleostomy site. C represents the resulting
medial axis.

voxels. In order to extract a robust estimate of the concentration from the scalae,
we define the concentration at each medial axis location as the average of concentrations in a plane through that medial axis location and normal to the medial axis.
Normal planes are obtained by defining a differentiable curve through the discrete
set of voxels on the medial axis and by identifying the normal and binormal vectors
to the curve. Cubic splines provide a mechanism for defining such a differentiable
curve; a series of three cubic splines are fit to the three components of the medial
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axis, and then the cubic splines are reparametrized in terms of arc length. This
re-parameterization serves two purposes: the continuous curve can be used to divide the scala equally, and tangent, normal, and bi-normal vectors can be obtained
by first order differentials at evenly-spaced points along the medial axis. Planes
spanning the normal tangent and bi-normal vectors are obtained by interpolating
intensity values from the scan along these vectors. Average voxel intensities are
extracted in a 7-voxel diameter circle about each re-parameterized axis point, followed by conversion of average intensity to concentrations in mg/ml using the linear
conversion defined in Section 2.3.2. The concentration profile extracted from the
baseline scan is subtracted from infusion scans concentration profiles to account for
any values not representing Iopamidol concentrations. This procedure is repeated
for the three main scalae to obtain the concentration profiles required for modeling
pharmacokinetics, which is explained in the consecutive chapter.

3.3

Results: Atlas based Segmentation

This work involved 17 animal experiments, out of which all the experiments were
used to test and refine the registration and segmentation algorithms. Iopamidol infusions from three experiments were used for determination of transport parameters,
and for development and testing of the pharmacokinetics model.
Fig. 3.5 shows the results of registration and segmentation of the cochlea. Results are displayed as the difference between stages of registration in three orthogonal
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Figure 3.5: The registration results are shown as a difference of the baseline scan
and atlas after registration. The difference values are seen in different values of gray.
Left - difference after affine registration stage, and Right - difference after final Bspline registration stage. The lower right saggital view in both is shown with the
segmented labelmaps superimposed. [Blue: ST, Green: SM, Yellow: SV]. On the
colorbar to the right, 0 (black) represents 100% alignment of cochlea bony walls and
scala boundaries in the atlas with those in the scan, whereas 1 (white) represents
0% alignment. It can be observed that the ST label map in the affine stage result
overlaps the cochlear wall, which is resolved after the B-spline stage.[A-Axial, CCoronal, and S-Sagittal orthogonal plane].

views. For visual assistance, the difference has been scaled between 0 (100% overlap)
and 1 (0% overlap). The intensity values inside the scala are different for the atlas
and the scan owing to their different imaging modalities. Registration accuracy is
quantified using the Jaccard Similarity Index [73] which calculates the ratio of intersection of segmented region with ground truth to their union. We take the Jaccard
similarity index of selected manually labeled label map slices with the equivalent
slices of registered label map. The overlap after the affine stage was calculated to
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be 58.28%, which improved to 79.61% after B-spline stage as seen in Fig. 3.5. The
region outside the cochlea is empty in the atlas, whereas it is filled with various
tissues in the scans resulting in lower Jaccard index. Moreover, due to variation in
the cochlea of the animal used in the atlas compared to the animals used in our
experiment, there will be inaccuracies in the registration result.

3.4

Results: Concentration Extraction

Fig. 3.6 shows the extracted concentrations of expirement-II. The concentrations
are normalized to the tube tip concentration and displayed as a percentage of the
length of the scala. Concentration profiles are labeled 10, 40, 70, 100, 130 min, to
approximate the temporal mid-point of each scan. The concentration peaks do not
align across scala in the plots of Fig. 3.6 primarily due to length normalization,
with a small contribution due to zero-point selection. Visualization of the location
of peak concentration within each scala in the 3D cochlear model revealed the peaks
do indeed align. The Euclidean distance between medial axis peak locations were:
0.45mm (SV-SM), 0.47mm (ST-SM), 0.75mm (ST-SV).
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Figure 3.6: Top row shows the contrast agent seen in the cochlea over time. STblue, SM-green, SV-yellow, represent the three scalae. Bottom row shows extracted concentration from a sample experiment (experiment - II) along the length
of each scala over time. The approximate position along the length of scala relative
to the defined zero point for each cross-section labeled in the baseline µCT scans
are: (1) ST 5%, SM 15%, SV 25%, (2) ST 40%, SM 45%, SV 45%, (3) ST 70%, SM
80%, SV 80%, and (4) ST 97%, SM 98%, SV 97%. Note the air bubble in ST is
evident in the scan.
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Chapter 4
Segmentation: Convolutional
Neural Network

Traditional segmentation techniques can model the region contours well, but at the
cost of computation time. Most of these methods take hours to run on a CT or
MRI image due to processign in 3D volumes as opposed to processing 2D slices.
Machine learning techniques on the other hand can give equivalent performance
when trained on the exemplar segmentations, and they can perform segmentation
on new, unseen images during inference within few seconds. Although there are
ample machine learning techniques, both supervised and unsupervised to perform
segmentation, we use state of the art Convolutional Neural Networks (CNNs) to
design our segmentation model.
71
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4.1

CNN: Background

Atlas-based segmentation techniques can have good performance, however, they rely
on computationally expensive deformable registration techniques that can require
minutes to hours to run. This computational time restricts the ability to process
multiple images and extract concentration from them, leading to slower experiment
turnaround time.
An alternative to atlas-based segmentation that avoids deformable registration
of an atlas to each new animal model is to employ modern segmentation techniques
based on CNNs [74, 75, 76]. CNNs can achieve performance similar to that of
atlas based segmentation in a fraction of the time, usually within seconds during
inference. Moreover, CNNs can accommodate a high degree of model non-linearity
that is required to get exact region boundaries between anatomies. Fully convolution networks were introduced by Long et al. to perform segmentation on tumor
histopathology slides [77]. CNNs for segmentation typically use a fully convolutional
encoder-decoder architecture [74]. Later, U-Net was introduced by Ronneberge et al.
[57] to do segmentation of neuronal structures in EM stacks and cell segmentation
in light microscopy images. U-Net introduced skip connections between the encoder
and the decoder branches. These skip connections help with vanishing gradients
that can occur in training networks with large number of parameters like those used
to perform segmentation. Since the majority of anatomies are imaged using MRI
and CT (3D images), networks that segmented these images in 3D were introduced.
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The same author extended the work to 3D U-Net [75] to segment Xenopus kidneys.
Following similar skip connections, V-Nets were introduced by Milletari et. al [3]
whose major contribution was replacing of pooling operations with strided convolutions. This network was used to segment the prostate in the PROMISE 2012
dataset. We employ a simplified version of V-Net in our work which is explained in
the next section.

4.2

V-Net: Architecture

V-Net [3] as shown in Fig. 4.1, is a CNN architecture that was designed for segmenting volumetric (3D) images, and it has shown good performance on datasets with
less than 100 samples when used along with data augmentation. V-Net is comprised
of an encoding and a decoding branch, that focuses on constructing a representation
of the input in the bottleneck or middle layer. This is similar to a U-Net but has
few key differences. Both the encoding and the decoding branch contain blocks that
constitute a cascade of one to three convolutional layers with 5 × 5 × 5 kernels. In
any one such block, a residual function is learnt, which is essentially an attempt to
learn the residue or the difference between the input and predicted output of any
layer. This is achieved by taking the input going into the first convolutional layer
of the block and adding to the output of the last convolutional layer. This residual
learning ensures better convergence compared to an U-Net. Another key difference
to U-Net is the use of dual strided 2 × 2 × 2 convolution in-place of a max pool
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Figure 4.1: Original V-Net [3].

layer. This doubles the channel size without the loss of information as is the case
with pooling layers. Moreover, PReLU is used as the activation function instead
of ReLU. Similar blocks are present in the decoding branch, with the upsampling
between blocks performed by 2 × 2 × 2 deconvolution layers with stride of 2. The
output of the decoding branch is passed through a 1 × 1 × 1 convolutional layer with
output channels equal to the number of segmentations plus the background.
Since overfitting is a certain possibility when using small datasets to train networks like V-Net with large number of parameters (around 43 million), we make
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Figure 4.2: Simplified V-Net architecture. Block 1 and 9: single convolution layer,
block 2 and 8: 2 convolution layer, rest of the blocks have 3 convolution layers. Red
dotted lines represent connections that transfer information from encoder to decoder
so that location information lost during encoding can be retrieved.

a few modifications to the network. The first modification downsamples the input
image. We discuss the observations of this network further in section 4.5. The second modification increases the receptive field by replacing regular convolutions in
every block of V-Net with dilated convolutions. The third modification reduces the
network parameters significantly with a tradeoff in performance, enabling an image
to be segmented in a clinical setting, without a GPU, in under two seconds. These
modifications are further discussed in the section below.
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4.2.1

Network Modifications

V-Net for segmenting volumetric images has shown good performance on datasets
with fewer than 100 samples. It is comprised of an encoding and a decoding branch,
and the output is collected after the decoding branch by applying soft-max to a
convolutional layer that has a kernel size of 1 and has 4 output channels (i.e., three
channels for each segmentation mask and one channel for background, which can be
modified based on the dataset). We use a simplified version of V-Net, as shown in
Fig. 4.2. The pooling operations for downsampling between blocks are replaced by
strided convolutions to improve the memory footprint of the network. Additionally,
we include batch normalization layers after every convolutional layer in order to
avoid over-fitting.
To further improve segmentation performance on the cochlear µCT images, we
explore the following modifications to V-Net, which are illustrated in figures 4.3,
4.4, and 4.5:
• Network 1: Inspired by multi resolution image processing using image pyramids
[78], we downsample the input by a factor of two before feeding it to the network.
In addition, we remove the fourth of the five stages of the encoder network to
ensure that the dimensions of the image are not reduced by too much. This
ensures that the network sees more of the image at every convolution step and
reduces the memory required for processing. The output convolution layer is
upsampled to the original image size before passing it to the soft-max layer.
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• Network 2: At every encoding and decoding stage in V-Net, the convolutional
layers are changed to have kernel size of three, with dilations of one, two, and
three in the first, second and third convolutional layers. This idea was previously
proposed for 2D dense segmentation networks to increase the receptive field of the
kernels[79], and it yielded significant performance improvement in that setting.
Although V-Net already has a theoretical receptive field of 551 × 551 × 551 at the
output, our modification makes the receptive fields larger in the initial layers of
the network, enabling the network to learn better features.
• Network 3: Most fully convolutional networks have millions of parameters and
require a GPU to evaluate in a reasonable time. To ensure that our V-Net can run
in real time on a CPU in a clinical setting, we reduce the number of channels in

Figure 4.3: Network 1: Downsampling input and upsample the output, with removal of a block to ensure proper encoded input size.
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Figure 4.4: Network 2: Dilated convolutions at every block.

Figure 4.5: Network 3: Decreased number of convolutions, incidentally decreasing
the number of channels in each block.

the convolutional layers by a factor of four, which reduces the number of trainable
parameters from 43.7 million to 1.05 million.
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Dataset

The dataset for training V-Net was derived from the original µCT scans. Dataset
consists of µCT scans of the heads of 21 mice. Each µCT scan has resolution 16 ×
16×16µm, which is high enough to resolve the ST, SM, and SV compartments of the
cochlea. The details of scan procedure is explained in-detail in Chapter 2. Briefly,
for each mouse, a baseline scan is captured (e.g., Fig. 4.6), and then a contrast agent
is infused into the left cochlea at a constant flow rate through a cochleostomy that
is drilled at the base of ST. After infusion, the mouse is scanned from 4 to 6 times.
The basal region of the left cochlea becomes saturated with the contrast agent after
the baseline scan, making compartment boundaries indiscernible. This yields one
image useful for segmentation from the left cochlea, and four to six images from the
right cochlea. For our dataset of 21 mice, we have a total of 137 images.

Figure 4.6: Left: 2-D slice from µCT image of the left cochlea of a mouse at baseline.
Right: corresponding slice of ground truth masks of ST, SM, and SV.
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Ground truth masks of ST, SM, and SV are constructed for each cochlear image
by automatic B-spline deformable registration [67] of a cochlear atlas [2] using Insight
Toolkit (ITK) [80] followed by visual verification. In all cases, normalized image
correlation after deformable registration was -0.85±0.05 (best = -1). In some cases,
extra tissue and bone was included in the periphery of the cochlea, preventing the
registration metric from reaching -1.

4.4

Network Training

All networks were implemented and trained using the Pytorch framework. The
dataset was divided into 70% training, 20% validation, and 10% testing on a permouse basis. Care was taken to maintain distribution of left and right cochlea among
the split. All images in the dataset were scaled to a uniform size of 128 × 128 × 128
voxels. The dataset was augmented to randomly include elastic transformations
[81] with elasticity coefficient, σ = 6, and intensity of deformation, α, chosen randomly between 0 (no transformation) and 50. Due to possible class imbalance, the
generalized Dice metric [82] was used for the loss function.
We performed training on a workstation with 64GB of system memory, Intel(R)
Core(TM) i7-7700K 4.2 GHz CPU, and a NVIDIA Titan Xp having 12 GB of
memory. We used Adaptive moment estimation (Adam) [83] for optimizing the
network after every mini-batch, and we used a batch size of 2 due to limited data
and GPU memory constraints. The training was started with a learning rate of
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5e−4 , and tuned between 1e−3 to 1e−5 for different networks. The weight decay
term was adjusted to 0.1×learning rate. Each model was trained for approximately
10 hours for 250 epochs. Test images were segmented from trained models in less
than two seconds. And in the case of Network 3 with significantly reduced number
of parameters, each image was segmented within a reasonable time of 9.4±0.52
seconds.
We initialized our training in two ways: (1) from scratch, and (2) by fine-tuning
weights learned by training the stock VNet on BraTS 2019 T1 weighted contrast
enhanced images. Although the BraTS dataset is meant for tumor segmentation,
the general features learnt by the encoder may be useful for segmenting cochlear
compartments. We transferred the complete BraTS pre-trained network as it is,
fine tuned by training for less than quarter of the time (50 epochs) on the cochlea
dataset, and predicted the segmentations on the test set.

4.5

Results

The network was exposed to inter-animal experiment variability, which was further
increased by the augmentation. As explained before, each batch contains only two
images to account for the dataset size, and high GPU memory requirement for 3D
network and images.
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Figure 4.7: Reference masks vs. predicted segments, ST, SM and SV in cyan,
yellow and maroon respectively. Effect of network downsampling on fine structures
and smoother region boundaries predicted by V-Net can be seen in red ovals 1 and
2 respectively.

V-Net Segmentation
Fig. 4.7 shows 2-D and 3-D visualizations of segmentation results as compared to
reference masks. As can be seen in the figure, there are some minor segmentation
errors. The narrow section as seen inside the first oval is not complete; this might
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be due to the section disappearing during encoder downsampling, resulting in the
network not learning features of that particular section of the scan. The second oval
shows an area where region boundaries are smoother than what is expected versus
the reference masks.
For each network, performance was evaluated using Jaccard index (Intersection
Over Union - IOU) as shown in equation 4.1 on the validation set, which contained
14 volumes. The Jaccard index between two regions A and B is defined by:

J(A, B) =

A∩B
,
A∪B

(4.1)

Performance results are shown in Table 4.1. Additionally, metrics in Table 4.2
show that CNN based methods can surpass atlas based methods in terms of performance. However, we still cannot ignore the fact that atlas based methods provide
great performance, especially in the absence of well curated datasets that are needed
for CNNs. To prove the feasibility of transfer learning using this learned model,
the same network was trained using BraTS ’18 dataset, and fine tuned on cochlea
dataset. The training time was reduced by 75%, but performance was reduced to
70.64% (IOU).
It is important to note that the reference segmentations were constructed by
visually verifying the results of atlas-based segmentation, rather than by manually
labeling every cochlear compartment in every volume. In this sense, it can be
argued that our V-Net is actually learning how to mimic the performance of atlas-
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Table 4.1: Performance metrics for V-Net: Stock, Network 1 (Net 1), Network 2
(Net 2) and Network 3 (Net 3) in terms of Jaccard Index averaged over all segments
(in %) and dice loss
Architecture
Stock
Net 1
Net 2
Net 3

Avg. Jaccard Index
79.345%
81.5%
83.382%
76.486%

Final Dice Loss
0.1709
0.1471
0.1482
0.2069

Table 4.2: Comparison of performance of atlas based registration and segmentation
with CNN based V-Net segmentation
Method
Avg. Jaccard Index

Atlas
79.61%

V-Net Dilated V-Net
79.345%
83.382%

based segmentation. We argue, however, that this approach still has merit if: (a)
segmentation of new (unseen) scans can be performed much more rapidly, and (b)
concentrations measured from the scalae segmented by our proposed networks are
consistent with the concentrations measured from the scalae segmented by atlasbased segmentation methods.

Since test volumes can be segmented through our V-Net architectures in less
than two seconds (on a GPU), and atlas-based segmentation requires minutes to
hours of effort (often with user intervention) to perform the necessary deformable
registration step, our V-Net segmentation strategy is certainly much more rapid
than atlas-based segmentation. Having observed only minor translations between
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baseline and other timepoint scans, we transfer baseline V-Net segmentation using
fast rigid registration.

Concentration Extraction
Before comparing the concentrations extracted from atlas and V-Net based segmentations, we compare the medial axis from both segmentations, given that in the end
concentrations are extracted around the medial axis. To this end, the discrete medial axis points from the segments are reparameterized in terms of arc length. This
reparameterization allows us to calculate distances between corresponding points on
both medial axes in a continuous space. We use Euclidean distance as our metric.
The error plots of these distances in ST, SM and SV are shown in Fig. 4.8. The
average distance between both medial axes in terms of physical units for ST, SM
and SV computed across all experiments are 0.197mm, 0.138mm, and 0.162mm,
respectively. These are less than 7% of the total arclength in millimeter. The large
distances in distances at the start and end of medial axis in case of experiment 1,
might be due to the manual selection of start and end points. Moreover, these difference in medial axes have little consequence on the final extracted concentrations
as seen in Fig. 4.9.
Finally, consider the extracted concentrations in Fig. 4.9, which illustrates an
example of concentrations extracted from ST using atlas based segmentation versus
using V-Net based segmentation. Concentrations are obtained from a seven-voxel
diameter window around the medial axis of the segment. Note the dip in concen-
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Figure 4.8: Error in distances compared between medial axis derived from compartments obtained by atlas and V-Net based segmentation. The distances are
calculated for three sample experiments. Top: ST. Middle: SM. Bottom: SV
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Figure 4.9: Concentration from ST at 10, 40, 70, 100, 130 mins. Top: From atlas
based method. Bottom: From CNNs. x-axis represents the length of ST from base
to apex in percentage and y-axis represents the concentration of the contrast agent
in mg/ml.

tration seen in scan 2 due to the air bubble introduced during infusion as explained
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Figure 4.10: Errorbar representing relative error between atlas-based segmentation
vs. V-Net segmentation. x-axis represents the length of ST from base to apex in
percentage and y-axis represents the relative error averaged over all scalae for each
timepoint scan in percentage.

in section 4.3. There are no significant visual differences in the plots. In addition
to this, Fig. 4.10 emphasizes the minute difference in extracted concentrations by
calculating the average relative error over all timepoints in ST = 3.37%, SM =
4.81%, and SV = 19.65%, between atlas-based segmentation versus V-Net segmentation. In terms of absolute concentration difference, these are equal to 1.02 mg/ml,
0.91 mg/ml, and 1.1mg/ml in ST, SM and SV, respectively. It is to be noted that
concentration throughout the length of SV is lower than 50 mg/ml; hence, small
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changes in concentration yield large relative error. The mean relative error between
atlas-based segmentation versus V-Net segmentation remains low in all the mice,
which can be seen in the errorbar plot in Fig. 4.10. The lower concentration of the
contrast agent due to it diffusing slowly towards the apex in the first 20 minutes of
the experiment, may be the cause of the impulse error values seen in the errorbar
of scan 2.
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Chapter 5
Pharmacokinetic Model
The spatio-temporal concentration profiles that are extracted for the ST, SV, and
SM can be used to estimate diffusion and transport parameters of a pharmacokinetic
model describing transport and clearance of drugs in the murine cochlea. The model
is built off of the model in [84], with significant modifications to the equations and
the parameters used. The main differences to our model are the inclusion of concentration based diffusion coefficient, considering advective flow from cochleostomy site
to the cochlear aqueduct, calculating leakage out of cochleostomy site as a function
of time, transport only between ST-SM and SM-SV, and with clearance directly
out of SM. Fig. 2.2 provides a graphical view of the kinetics considered by our
model within the cochlea. In this section, we describe the pharmacokinetics of drug
diffusion and transport within and across the ST, SM, and SV with the help of
a compartment model, and then we show how the spatio-temporal concentration
91
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profiles extracted from the µCT scans can be used to solve the inverse problem of
estimating diffusion and transport parameters.

5.1

Drug Transport and Diffusion

As represented in Fig. 2.2, our model relies on three key assumptions: there is an
advective flow component from the cochleostomy site towards the cochlear aqueduct,
diffusion mediated transport is responsible for transport from base to apex, and
there is transport between scalae and to clearance. SL primarily overlaps with SM
in the mouse cochlea, so clearance in the model is restricted to transport out of SM
considering SL as a membrane.

5.1.1

Compartment Model

The pharmacokinetic model can be represented as compartments as shown in Fig.
5.1 and the equations can be generalized based on diffusion coefficient within the
compartment, and transport coefficients between the compartments.
Consider three compartments representing ST, SM, and SV with concentrations
CST , CSM and CSV that vary along the length of the scalae. The advective flow from
cochleostomy site to cochlear aqueducy (CA) in ST is defined by time dependent
flow rate F . The transport between ST-SM and SM-SV are defined by KST −SM and
KSM −SV , and by KSM −clearance between SM and clearance. Fluid flow from SV into
the vestibular system and to ST through heliocotrema at the apex is negligible in
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Figure 5.1: Three compartments for scala tympani (ST), scala media (SM) and
scala vestibuli (SV) make up the compartment model. CST , CSM and CSV represent
spatially varying concentrations in ST, SM and SV respectively. F is the flow rate
from CO-CA that varies with respect to time, and D is the diffusion coefficient.
K’s denote the transport parameters between compartments ST-SM, SM-SV and
SM-clearance. Continuous flow is represented by solid arrows and diffusion through
membranes is represented by dashed arrows.

the case of mice. The concentration within SL, representing clearance, is held at 0.
The detailed diffusion equations as shown in the next section 5.2 can be simplified
to explain the kinetics in each compartment as shown below.

ST: CO to CA :

ST: CO to apex :

SM :

∂CST
∂CST
=F
∂t
∂x

i
∂CST
∂ 2 CST h
−
K
(C
−
C
)
=D
ST
−SM
ST
SM
∂t
∂x2

(5.1)

(5.2)

∂CSM
∂ 2 CSM h
=D
− KST −SM (CSM − CST )
∂t
∂x2
i
+ KSM −SV (CSM − CSV ) + KSM −clearance (CSM )
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h
i
∂CSV
∂ 2 CSV
SV :
=D
− KSM −SV (CSV − CSM )
∂t
∂x2

(5.3)

The diffusion coefficient D is assumed to be the same for all the three compartments.

5.1.2

Diffusion Coefficient and Decay Factor (Gamma)

For a solute molecule with molecular weight M W and viscosity of the solution η,
the theoretical diffusion coefficient and gamma term are defined as:

Dtheoretical =


rH =

kB T
,
6πηrH

3M W
4πρN0

(5.4)

 13
,

(5.5)

where, kB , T, rH , ρ and N0 denote Boltzmann constant, temperature in Kelvin, hydrodynamic radius, density of solute molecule, and Avogadro’s number respectively.
The hydrodynamic radius in particular is important here as it can be used as a first
order scaling of transfer coefficients to any new molecule as described in section 5.5.
Viscosity was observed to change with concentration of the Iopamidol solution
used in our experiments, consistent with empirical measurements in other pharmacokinetics work [85, 86]. However, there is no closed form equation between viscosity
and concentration that can be integrated into equation 5.4. The relation for con-
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centration dependence was provided by [87], wherein Fick’s second law is modified
using the Einstein-Stokes equation [88]. This relation to calculate the concentration
dependent diffusion coefficient is shown below:

D(x, t) = 

D0
1 − γc̄(x, t)

2 ,

(5.6)

where D0 is the theoretical diffusion coefficient (equation 5.4) at zero concentration
and with η presented as the zero concentration solution viscosity. γ is a learned
parameter characterizing the concentration dependent decay in the diffusion coefficient. This decline in diffusion coefficient with increasing concentration has been
empirically measured for Iopamidol solutions from 0.08M to 1M by Fontanive [89].

5.1.3

Initialization of Parameters

For implementation, KST −SM , KSM −SV , and KSM −clearance and γ are initialized to
a random value between 0 to 1, and concentrations along length in all three scalae
are initialized to 0 at time zero. The concentration at every time step can now be
calculated using these initial estimates. These calculated concentrations are later
used to optimize the randomly initialized parameters as shown in section 5.4. Each
scan is an aggregate of 20 minutes of scan time, making the concentrations profiles
obtained from each scan a temporal average of 20 minutes. For practical implementation, the time step was defined to be ∆t = 0.1sec, making it possible to simulate
a concentration profile for every ∆t and average those for six 20-minutes intervals
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to replicate the scanning process. Therefore, the equation to average concentrations
over I total time steps is shown below:

I


1 X
C(n) =
c̄(n, k − 1) + ∆c̄(n, k) ,
I k=1

(5.7)

where C(n) is the estimated concentration averaged over 20 minutes at nth point on
the scala, so that it can be compared to the corresponding concentration extracted
from the scans.

5.2

Diffusion, Advection, Permeation: Supporting Concepts

Solute spreading processes in our model (LP model) are a combination of transport
processes described within a compartment by diffusion and advective flow, and those
describing interscala communications and clearance by permeation. Although fluid
transport in the inner ear can be explained by diffusion and permeation, in our case
of contrast agent delivery from cochleostomy site (CO) with exit out of cochlear
aqueduct (CA), we have to consider advective flow in that length of scala. The
equations below define the three paradigms of transport in a small tube, and then
combine them to define our cochlear pharmacokinetic model.
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Figure 5.2: Cylindrical tube of length L and cross sectional area S, with concentration c̄(x) at time t flowing through it at velocity v. The volume of the section,
V would be Sdx. The section has a semipermeable membrane of area A in contact
with another compartment of concentration b̄(x, t). Permeation takes place through
the semi-permeable membrane. Diffusion takes place in the x direction while permeation takes place across y.

5.2.1

Diffusion and Advection

Diffusion is the process of movement of solute particles from a region of high concentration to a region of lower concentration. Fick’s first law of diffusion relates the
solute flux j or the amount of solute passing through unit area per unit time with
the change in concentration c(x) per unit length x. D is the diffusion coefficient or
diffusivity in mm2 /s.
j = −D

∂c(x)
∂x

(5.8)

Consider a cylindrical tube of certain length, L in the x direction as shown in
Fig. 5.2. It has a cross sectional area S. A solution flows through it at velocity
v. The concentration of the solution at any point along the length, L is c̄(x) which
represents the average concentration across that section. The volume, V over any
infinitesimally small length would be Sdx.
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Since we are assuming transport (diffusion and advection) along x, the solution will not be well mixed in this direction. The flux at steady state or dynamic
equilibrium would be,

jx = −D

dc̄(x)
+ vc̄(x)
dx

(5.9)

For non-steady state diffusion, Fick’s second law (for diffusion only) or the
diffusion-advection equation needs to be used along the x direction. This is derived from equation 5.9 using the mass continuity equation:

∂c̄(x, t)
+ ∇jx = 0,
∂t

(5.10)



∂c̄(x, t)
∂c̄(x, t)
+∇ −D
+ vc̄(x, t) = 0.
∂t
∂x

(5.11)

In scalae of small cross sectional areas, it can be assumed the concentration is
radially uniform [84], so ∇ can be replaced by ∂/∂x; i.e.,

∂c̄(x, t)
∂
∂c̄(x, t)
+
(−D
+ vc̄(x, t)) = 0,
∂t
∂x
∂x

(5.12)

∂c̄(x, t)
∂  ∂c̄(x, t) 
∂
−
D
+
(vc̄(x, t)) = 0,
∂t
∂x
∂x
∂x

(5.13)
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∂  ∂c̄(x, t) 
∂c̄(x, t)
∂c̄(x, t)
=
D
−v
.
∂t
∂x
∂x
∂x

(5.14)

If D is constant and v is zero, the equation reduces to Fick’s second law. When
D varies with concentration, we consider the concentration dependent diffusion coefficient as defined in equation 5.6:

D(cv/v ) =

5.2.2

D0
(1 − γcv/v )2

(5.15)

Diffusion and Advection in a Tube of Varying Cross
Sectional Area

Platak C. S. [90] derived Fick’s second law for diffusion within a long tube. We
extend this derivation to include a non constant diffusion coefficient as well as fluid
flow through the tube [72]. Consider a thin tube of varying cross section S(x), such
that its length is much longer than its cross sectional area or radius at any point.
Again we assume the concentration across a cross section to be well mixed at all
instances. The solution is considered to be incompressible and flowing into the tube
at a volumetric flow rate F (t) resulting in a velocity of the fluid v̄(x, t) at each
point along the length, where v̄(x, t) = F (t)/S(x). Similar to the mass-continuity
equation in 5.10, we start with the equation:
∂
∂t

ZZ

∂
c(x, y, z, t) dS = −
∂x
S(x)

ZZ
jx (x, y, z, t) dS.
S(x)

(5.16)
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Since the diffusion coefficient is concentration dependent, it can also be considered to be a function of space and time. So the above equation 5.16 can be rewritten
as

∂
∂t

ZZ
c(x, y, z, t) dS =
ZZ
h
i
∂c(x, y, z, t)
∂
− D(x, y, z, t)
+ v(x, y, z, t)c(x, y, z, t) dS.
−
∂x S(x)
∂x
S(x)

(5.17)

Since we assume that the concentration is constant along the radius of the tube,
we can integrate along the y and z direction. This reduces equation 5.17 to:

S(x)

i
∂c̄(x, t)
∂ h
∂c(x, t)
=
D̄(x, t)S(x)
− S(x)v̄(x, t)c̄(x, t) .
∂t
∂x
∂x

(5.18)

Since the assumption has been made that the solution is well mixed across cross
sections,

∂c̄(x, t)
∂c(x, t)
=
.
∂x
∂x

(5.19)

Also D̄(x, t) = D(c̄(x, t)), which we will henceforth denote as D(x, t), reducing
the equation 5.18 to:

i
∂c̄(x, t)
1 ∂ h
c̄(x, t)
=
D(x, t)S(x)
− S(x)v̄(x, t)c̄(x, t) .
∂t
S(x) ∂x
∂x

(5.20)

S(x)v̄(x, t) can be replaced with F (t), so the final form of the equation will be:
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1 ∂ h
c̄(x, t) i F (t) c̄(x, t)
∂c̄(x, t)
=
D(x, t)S(x)
−
, 0 ≤ x < L,
∂t
S(x) ∂x
∂x
S(x) ∂x

(5.21)

∂c̄(L, t)
= 0, x = L,
∂x
c̄(x, 0) = c¯0 (x), t = 0.
This initial boundary value problem represents longitudinal transport within a tube
of varying cross sectional area.

5.2.3

Transport Across a Membrane: Permeation

A semi-permeable membrane allows only certain substances to pass through it, so
while perilymph and endolymph do not pass through the membranes within the
cochlea, some contrast agents and drugs delivered into those regions do. The motion
of the solute molecules are not independent of those of the solvent, since the fluids
in the inner ear are at rest, movement between compartments also take place via
diffusion. In such cases the transport is referred to as permeation and in this case
the solute flux is proportional to the inter-compartmental concentration gradient:

j ∝ ∆c,

(5.22)
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j = ωRT ∆c,

(5.23)

where ω is the membrane permeability, R is the ideal gas constant, and T is
the temperature in Kelvin. Since we are only concerning ourselves with the term
collectively, we will denote the proportionality of constant as the transfer coefficient
K, so that 5.23 becomes:

j = K∆c

(A16)

Clearance refers to the removal of the drug or contrast agent from the organ.
Clearance in our model is represented by the transfer coefficient between the scala
media and blood. While clearance is usually represented by transport out of spiral
ligament (SL) to blood, we consider clearance directly out of scala media due to
the limitations in extracting concentrations out of SL, and we consider SL as a
membrane itself.
We now take into consideration two cylindrical compartments with volumes V
and V ′ and concentrations c̄(x, t) and b̄(x, t) with transport between them occurring
through a membrane of area A as shown in Fig. 5.2. The concentration in each section of length dx is considered to be radially uniform. This means that at each point
along x, the concentration is well mixed across the cross sectional area S, or instantaneous mixing occurs across the cross section when any change in concentration
occurs at any point within it.
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The flux in the y direction would be:

jy = −K(c̄(x, t) − b̄(x, t)),

(5.24)

where K depends on the physical properties of the membrane such as thickness,
pore size and density, and its units are in mm/s. c̄(x, t) is the concentration in the
current compartment and b̄(x, t) is concentration in an adjacent compartment.
Representing the flux jy in terms of the number of moles Ny ,
∂Ny
= −K(c̄(x, t) − b̄(x, t)), and
A(x)∂t

(5.25)

∂Ny
= −KA(x)(c̄(x, t) − b̄(x, t)).
∂t

(5.26)

Dividing both sides by the volume of the section, V(x), we have:
∂Ny
KA(x)
=−
(c̄(x, t) − b̄(x, t)), and
V (x)∂t
V (x)

(5.27)

∂ c¯y (x, t)
KA(x)
=−
(c̄(x, t) − b̄(x, t)).
∂t
V (x)

(5.28)

It can be seen that the change in the number of moles of the substance is independent
of the volume it is in and is only dependent on the area of the membrane it is trying
to permeate out of and the concentration gradient between the compartments. This
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is due to the fact that irrespective of the size of the compartments, permeation will
take place till the solute is equally dispersed throughout both compartments; i.e.,
their concentrations are equal.

5.2.4

Combined model for Diffusion, Advection and Permeation

We now consider a model with all three modes of transport; concentration dependent
diffusion, advection and permeation through a tube of varying cross sectional area.
Fig. 5.2 shows a single infinitesimal section taken into consideration. The length of
the whole tube is L and the initial concentration is c¯0 (x) = c̄(x, 0).
In equations 5.13, we can say that the concentration in a compartment can be the
combination of rate of change of concentration along the length of the compartment,
which is given by equation 5.21, and rate of change of concentration across the
membranes between two compartments, that’s shown in equation 5.28. So the final
form of the partial differential equation can be written as ∂c/∂t = ∂cx /∂t + ∂cy /∂t.
Substituting ∂cx /∂t by equation 5.21 and ∂cy /∂t by equation 5.28, we get:
∂c̄(x, t)
1 ∂ h
∂c̄(x, t) i
=
D(x, t)S(x)
−
∂t
S(x) ∂x
∂x
F (t) ∂c̄(x, t) KA(x)
−
(c̄(x, t) − b̄(x, t)), 0 ≤ x < L,
S(x) ∂x
V (x)
∂c̄(L, t)
= 0, x = L,
∂x

(5.29)
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c̄(x, 0) = c¯0 (x), t = 0.

5.3
5.3.1

Learning-Prediction Model
Model Equations

A representation of the reduced model we use is given in Fig. B.5.3. Scala tympani,
and scala vestibuli are considered to have transport only with scala media. Clearance
to blood takes place out of the SL, however, SL being only 2 - 6 voxels thick (32
- 96µm), restricts concentration extraction from it. Instead, we treat the spiral
ligament as a membrane itself. The semipermeable membranes between scalae,
(basilar membrane between ST and SM, and Reissner’s membrane between SV and
SM) as well as transport between SM and blood are represented by dashed lines.
Solid lines represent bone or the inability for transport to take place out of the scala
through that boundary.
Contrast agent will be delivered at a certain flow rate at the base of ST. The
contrast agent flows out of the cochlear aqueduct. Over time, the agent diffuses
down the length of ST and up into SM and SV. So from the point of delivery up to
the apex, equation 5.29 reduces since v = 0, and from the point of delivery down to
the cochlear aqueduct, the equation will be used as is.
If x0 is the point of delivery, then the PDE governing transport from x0 to the
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Figure 5.3: Cross section of our 1D model, diffusion and advection are considered
to take place in a direction perpendicular to the plane of the page. Dashed lines
represent transport between scalae, solid lines represent no transport

apex will be
1 ∂ h
∂c̄(x, t) i KA(x)
∂c̄(x, t)
=
D(x, t)S(x)
−
(c̄(x, t) − b̄(x, t)), x0 < x < L,
∂t
S(x) ∂x
∂x
V (x)
(5.30)
∂c̄(L, t)
= 0, x = L,
∂x
c̄(x, 0) = c¯0 (x), t = 0.
The PDE for transport from the point of delivery down to the base in ST will
be:
∂c̄(x, t)
1 ∂ h
∂c̄(x, t) i F (t) ∂c̄(x, t) KA(x)
=
D(x, t)S(x)
−
−
(c̄(x, t) − b̄(x, t)),
∂t
S(x) ∂x
∂x
S(x) ∂x
V (x)
(5.31)
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0 < x ≤ x0 ,
∂c̄(0, t)
= 0, x = 0,
∂x
c̄(x, 0) = c¯0 (x), t = 0.

5.3.2

Discretization of Model

Consider the concentration c̄(x, t) within a scala along the length x, with cross
sectional area S(x) and volume V (x) where V (x) = S(x)dx. K denotes the transport
coefficient across the membranes between scalae and b(x, t) is the concentration in
a neighbouring scala, equation 5.31 simplifies to

∂ 2 c̄(x, t) KA(x)
∂c̄(x, t)
= D(x, t)
−
(c̄(x, t) − b̄(x, t)).
∂t
∂x2
V (x)

(5.32)

In order to discretize equation 5.32, consider the scala of length L to be partitioned into n equally sized intervals, such that x0 = 0, x1 = x0 + ∆x, x2 =
x0 + 2∆x, ..., xn = x0 + n∆x, where ∆x = L/n. Similarly, time is incremented
in steps of ∆t, such that t0 = 0, t1 = t0 + ∆t, t2 = t0 + 2∆t, ..., tk = t0 + k∆t.
Accordingly, terms of equation 5.32 can be approximated by their discrete equivalents. For discrete points (n,k), we get c̄n,k = c̄(xn , tk ); Dn,k = D(xn , tk ); Sn =
S(xn ); and so on. In practice,
forward difference as:

∂c̄(xn ,tk )
∂t

and

∂c̄(xn ,tk )
∂x

can be approximated using

108

Pharmacokinetic Model

c̄n,k+1 − c̄n,k
∂c̄(xn , tk )
c̄n+1,k − c̄n,k
∂c̄(xn , tk )
≈
; and
≈
.
∂t
∆t
∂x
∆x
∂D(xn ,tk )
,
∂x

For

and

∂S(xn )
∂x

d2 c̄(xn ,tk )
,
dx2

(5.33)

are approximated similarly using forward difference.

a second order central difference approximation is given by:

c̄n−1,k − 2c̄n,k + c̄n+1,k
d2 c̄(xn , tk )
≈
.
2
dx
∆x2

(5.34)

An important condition that ensures stability while approximating diffusion
equations using forward and central differences is to keep the time step ∆t lesser
than a bound that depends on the spatial partition size ∆x [91],

∆t ≤

(∆x)2
.
2D

(5.35)

During implementation, at every time point the concentration is calculated as:

c̄(n, k) = c̄(n, k−1 ) + ∆c̄(n, k),

(5.36)



where the concentration along the length of scala at the current time point c̄(n, k)
is the sum of the previous concentration and the difference in the concentration
between time steps.
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Estimating Diffusion and Transport Parameters

To estimate contact area between scalae, morphological dilation [92] is used to find
the region of intersection between different compartments. Morphological dilation
expands the label maps until the region of intersection is obtained between them.
This region of intersection is treated as the area of contact. To this end, the label
map of the semipermeable basilar membrane is used for contact area between STSM. In the absence of Reissner’s membrane from the atlas, we make use of the
SM and SV label maps to obtain contact area between them. For the transport
from SM-clearance, the intersection are between SM-SL is calculated similarly using
morphological dilation. Equation 5.2 to 5.3, take the area of contact A(x), volume
V (x) and cross sectional area S(x) as fixed quantities derived from the native atlas
as shown in equation 5.31. However, the transport coefficients K, concentration
dependent diffusion parameter γ, and D0 are initialized to random values between
0 and 1, and iteratively learnt using optimization.
Using the molecular weight of Iopamidol (MW = 777.08 g/mol), and density ρ
of the solute (2.204 kg/L), D0 can be theoretically calculated from equation 5.4.
However, the viscosity η of solution that Iopamidol would be diffusing into, which
in our experiments is perilymph, is unknown and is substituted with that of water
(0.68cP at 311K). This brings the calculated value of D0 = 6.7 × 10−4 mm2 /s.
However, in order to be precise with respect to perilymph in the mouse cochlea,
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Figure 5.4: The reduced 1-D model takes in the initial values for K, D0 , γ, flow
rate profile, and outputs the simulated concentration. The optimizer calculates
loss L based on simulated and extracted concentration, and updates the transfer
coefficients. The hyperparameters αK , αD0 , αγ , are provided to the optimizer. The
updated parameters are used by the model in the next epoch. This cycle is repeated
for n epochs.

D0 is also learnt with the remaining transport parameters and is comparable to the
calculated value.
Gradient descent is chosen as the optimizer for the learning process. It uses the

111

Pharmacokinetic Model

gradient of the cost function (first order difference between current and previous loss
values), to update the initialized parameters. The update is controlled by a hyperparameter known as the learning rate (α) that can speed up or slow down the update
over iterations. As described in the flowchart of Fig. 5.4, the model takes in the
initialized parameters and calculates the concentration profiles as output for every
time step using equation 5.36. These profiles are then averaged for 20-minute time
steps using equation 5.7. These are compared with their respective time points’
extracted concentrations and the loss is calculated using mean squared loss cost
function:
2
N 
1 X Csim (n) − Cscan (n)
,
L=
N n=1
Cmaximum

(5.37)

where Csim (n) is the averaged simulated concentration, Cscan (n) is the extracted
concentration from the respective time point and corresponding position. The maximum intensity value at the tip of the inserted cannula at the cochleostomy site
(Cmaximum ) is used to normalize the cost. The gradient (gradient: ∇, current iteration loss: L, previous iteration loss: L−1 ) considering D0 as an example, is given
by:

∇=

L − L−1
dL
=
.
dD0
∆D0

(5.38)

As shown in Fig. 5.4, the gradient for each parameter is multiplied by their
respective learning rate and subtracted from the previous parameter value to get
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the new parameter value for simulation in the forward model. The learning rate is
initialized to low values in the range of 10−2 to 10−3 and they remain unchanged
until the end of optimization. The optimization continues until the change in loss
is less than 0.01%.

The transport parameters are initially learnt by keeping a constant flow rate
profile with respect to time F in equation 5.1. Since the estimated ST volume
between the cochleostomy site and the cochlear aqueduct is only 35 nl in the mouse,
this region should be saturated almost immediately given the 32 nl/min flow rate.
We observed that in some experiments, the peak concentration was reached in 70
- 100 minutes (3rd to 4th time point after Iopamidol infusion), suggesting a leak
through the cochleostomy site that slowly sealed during the course of the experiment.
To estimate the flow rate including leakage over time, we simulated the concentration
exclusively at the infusion point, with the flow rate initialized to 32 nl/min. The
gradient of the error was calculated by comparing these simulated concentrations
with the extracted concentrations at the infusion point. The flow rate at each time
point was optimized using the gradient, and a final flow rate profile was obtained
by interpolating between the time points. The transport parameters are then relearned using the new flow rate profile that accounts for time-varying leakage at the
cochleostomy site.

113

Pharmacokinetic Model

5.5

Simulation for Different Molecules

For applications requiring infusion of molecules other than Iopamidol, D0 and K can
be scaled to the molecule under consideration. The theoretical diffusion coefficient
D02 can be calculated for a new solute molecule (2nd molecule) given the value of
D01 for Iopamidol (1st molecule), by using equation 5.4 and 5.5, we get:

rH
D02
= 1 =⇒ D02 = D01 ×
D01
rH 2

s
3

M W1 ρ2
,
M W2 ρ1

(5.39)

where molecular weight and density of the 1st molecule (M W1 , ρ1 ), and the 2nd
molecule (M W2 , ρ2 ) are known quantities. Similarly, transfer coefficients K are
scaled using the same relationship as equation 5.39 as shown below.
s
K2 = K1 ×

3

M W1 ρ2
,
M W2 ρ1

(5.40)

where K2 , and K1 represent the transfer coefficients for the 2nd and 1st molecule
respectively.
It is important to note that this pharmacokinetic model was constructed using molecules that can exhibit image contrast during µCT imaging. There are a
wide range of triiodo compounds (contrast agent used in this work is a triiodo compound) that can be imaged, however translation of pharmacokinetic parameters to
other compounds with therapeutic benefit is currently limited to the proposed scaling of D0 and K based on molecular weight and density of the solute as shown
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in eq. 5.39, 5.40. However, this scaling does not consider the impact of molecular properties on transport through biological membranes. Salt and Plontke [93]
proposed incorporation of lipophilicity and topological polar surface area (TPSA)
into cochlear pharmacokinetics to enhance translation to therapeutic compounds.
However, there are no known equations to enable direct incorporation into the K
values determined via the LP model or sampling/computational techniques.

5.6

Results: Extracted vs. Model Concentrations

Table 5.1 details the transport parameters extracted for each of the three different
experiments. The concentration dependent diffusion coefficient as shown in Fig.
5.5 has been normalized by the extracted diffusion coefficient at zero concentration
(D0 = 6.226 × 10−4 mm2 /s). The form of this decay is similar to that empirically
measured by Fontanive [89], however their more rapid decay was attributed to aggregation of Iopamidol molecules at high concentrations, with an estimated average
of 2.3 molecules per aggregate at a concentration of 0.8M. Although the Iopamidol
molecules in our solution do not aggregate, the change in diffusion coefficient can

Table 5.1: Learnt parameters from three experiments.
Experiments
KST −SM [10−3 mm/s]
KSM −SV [10−3 mm/s]
KSM −clearance [10−3 mm/s]
D0 [10−4 mm2 /s]
γ

I
0.71
0.35
0.042
6.23
-0.93

II
1.2
0.29
0.032
6.22
-0.91

III
1.1
0.52
0.033
6.23
-0.79

Mean Values
1.01
0.38
0.035
6.226
-0.87
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Figure 5.5: The curves represent the normalized diffusion coefficient as a function
of concentration based on the extracted γ parameter for each experiment. Concentration itself is expressed as a ratio of volume of solute by volume of solution (v/v),
which is used when both solute and solution are liquids.

be credited to increased interaction between Iopamidol molecules at higher concentrations. The black line shows the maximum value of concentration delivered in our
experiments, so all the values of the diffusion coefficients used by the model lie to
the left of this line.
Fig. 5.6 shows the extracted and simulated concentrations, and the error between
them (extracted - simulated concentration). The concentrations are normalized to
the tube tip concentration and displayed as a percentage of the length of the scala.
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Figure 5.6: Subplot A shows the contrast agent seen in the cochlea over time.
ST-blue, SM-green, SV-yellow, represent the three scalae. Subplot B shows concentrations along the length of each scala over time. the approximate position along
the length of scala relative to the defined zero point for each cross-section labeled
in the baseline µCT scans are: (1) ST 5%, SM 15%, SV 25%, (2) ST 40%, SM 45%,
SV 45%, (3) ST 70%, SM 80%, SV 80%, and (4) ST 97%, SM 98%, SV 97%. Top
row: extracted concentration from a sample experiment (experiment - II). Note the
air bubble in ST is evident in the scan. Middle row: the simulated concentrations
using the mean of the parameters. Bottom row: error between extracted and simulated concentrations (first time point excluded due to larger errors associated with
the air bubble which is not incorporated into the simulation model). The plots in
each column are for ST, SM and SV respectively. The average root mean square
error (RMSE) across all scalae and time points is 8.9%.
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The mean value of the learnt parameters over three experiments as shown in Table
5.1 is used in the forward simulations. As mentioned in section 3.4, concentration
profiles are labeled 10, 40, 70, 100, 130 min, to approximate the temporal mid-point
of each scan. Simulated results are the average results over 20 minute windows
centered on the labeled time to approximate the experimental paradigm. The concentration peaks do not align across scala in the plots of Fig. 5.6 primarily due to
length normalization, with a smaller contribution due to zero-point selection.

5.7

Results: Comparison with Fluid Sim

FluidSim is the gold standard in inner ear pharmacokinetics forward simulation
software published by Alec N. Salt [94]. Fig. 5.7 shows the simulated plots from both
LP model and FluidSim. The software considers a single fixed diffusion coefficient
calculated using molecular weight of the solute molecule. It uses half-times (t1/2 ) to
Table 5.2: LP model parameters shown adjacent to their respective converted half
times
Transport Membranes
ST-OC
OC-SM∗
SM-SV∗∗
SM-clearance∗∗∗
∗

LP model (K) [10−3 ]
N-A
1.01
0.38
0.035

OC-SM: V = 5.7 × 10−3 mm3 , A = 9.9 × 10−3 mm2

∗∗

SM-SV: V = 5.7 × 10−3 mm3 , A = 27.2 × 10−3 mm2

∗∗∗

SM-clearance: V = 4 × 10−3 mm3 , A = 17.7 × 10−3 mm2

FluidSim (half times) [minutes]
0.1
6.6
6.4
75
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Figure 5.7: Top row: simulation of delivery of 240mg/ml Iopamidol at 32nl/min for
140 min through a basal turn cochleostomy in ST using the LP model and FluidSim
v3.14. Bottom row: error calculated relative to extracted concentrations from the
Iopamidol infusion experiments. The RMS error in percentage for LP model is 8.9%,
and FluidSim is 12.46% with respect to extracted concentrations.

represent inter-scala transport instead of transport coefficients. In order to convert
our transfer coefficients (K) to half-times, a relation provided in [95, 96] is used.
Given a small cross section of volume V at the base of scala, with corresponding
area of contact with the adjacent scala A, then the relation between t1/2 and K is
given by:

0.693
KA
=
t1/2
V

(5.41)
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The cochlear aqueduct location is aligned in both models and presented as the
zero length point in ST. The zero points of SM and SV in FluidSim were determined
qualitatively by calculating the distance in mm from apex to zero point in LP model,
and zero point in FluidSim was fixed at the same distance. We used the average
values of the learned transport parameters for conversion to half times to use in
FluidSim. The values used for the simulation are presented in Table 5.2. Diffusion
coefficient D, in FluidSim was set to 5.9 × 10−4 mm2 /s based on molecular weight of
Iopamidol. FluidSim does not allow transport between ST and SM directly, rather it
incorporates transport from ST to organ of Corti (OC), and then to SM. To account
for these differences in the model structures, the OC-ST half time is set to 0.5 min
so that transport between ST to OC is fast. The FluidSim OC-SM half time is
equated to our ST-SM transport coefficient to approximate equivalent transport.
For clearance, SL-SM half time was equated to our SM-clearance transport, and
clearance half time out of SL was also set to 0.5 min. Within FluidSim, all half
times are provided for the 0% point of the scala, with the half times scaled along
the length based on the cross-sectional area of the scala from which transport occurs.
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5.8

Results: Transport Parameter from V-Net Segmentation

To showcase the validity of our V-Net based segmentation, we use the segmented
compartments to estimate the transport parameters in the pharmacokinetic model.
Table 5.3 shows the estimated transport parameters from V-Net segmentation compared to atlas-based segmentation. Shown for three sample experiments, the transport coefficients estimated from segmentations obtained from both atlas based and
V-Net based methods are similar. We use these transport parameters to simulate
concentrations with a starting flow rate of 32 nl/min and 240 mg/ml peak concentration of solute. The concentration profiles are seen in Fig. 5.8. It can be observed
that the simulations in both cases are similar, with the apex concentrations at the
130min timepoint in V-Net based method having a concentration of ≈51.6 mg/ml,
compared to ≈46.44mg/ml in atlas based method. Although the variations in extracted concentrations from both method falls within 1 mg/ml, we believe these
small variations could have caused the slightly higher difference in simulated apex
concentrations. However, this difference falls within the range of experimental variations.

To demonstrate the insignificant effect of small variations in concentration on
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Table 5.3: Estimated transport coefficient for three sample experiments, calculated
for both atlas based and V-Net based segmentations
Transport Coefficients
KST −SM [10−3 mm/s]
KSM −SV [10−3 mm/s]
KSM −clearance [10−3 mm/s]

Transport Coefficients
KST −SM [10−3 mm/s]
KSM −SV [10−3 mm/s]
KSM −clearance [10−3 mm/s]

Transport Coefficients
KST −SM [10−3 mm/s]
KSM −SV [10−3 mm/s]
KSM −clearance [10−3 mm/s]

Experiment I
Atlas based V-Net based
0.71
0.72
0.35
0.35
0.042
0.041
Experiment II
Atlas based V-Net based
1.2
1.2
0.29
0.291
0.032
0.031
Experiment III
Atlas based V-Net based
1.1
1.1
0.52
0.53
0.033
0.032

transport coefficients, we add Gaussian noise to the extracted concentrations and
then estimate the transport coefficients using the noisy concentrations. We determine the acceptable noise in extracted concentration to be 2.655 mg/ml through
sensitivity analysis of concentrations in µCT as shown in [39, 40]. We use a mean
of 0 and standard deviation of 2.655 to model the added Gaussian noise. The noise
is added separately for every timepoint and used to calculate the transport coefficients. This process is repeated for 10000 trials and the transport coefficient is
collected for every trial. Table 5.4 shows the mean and standard deviation of coef-
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Figure 5.8: Simulated concentrations from ST at 10, 40, 70, 100, 130 mins. Top:
Atlas based method. Bottom: V-Net based. x-axis represents the length of ST
from base to apex in percentage and y-axis represents the concentration normalized
to 258.827 mg/ml, the average observed maximum concentration at the end of the
infusion tube tip during experiments.

ficients over 10000 trials. The mean coefficient values almost equal to the average
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Table 5.4: Effect of noise in extracted concentration on transport coefficients over
10000 trials

Transport Coefficients
KST −SM
KSM −SV
KSM −clearance

10000 trials
Mean
Standard Deviation
−3
[10 mm/s]
[10−6 mm/s]
1.01
0.485
0.38
0.179
0.034
0.024

coefficient values of our three experiments. Additionally, the standard deviation
is three orders smaller than the mean values. This demonstrates that variations
in concentrations between experiments still converge on transport coefficients that
simulate concentrations profiles similar to the actual experiments.
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Extra Experimentation: Pulsatile Delivery

Another application of the LP model is exploration of different drug delivery paradigms
to optimize concentrations within the cochlea. This is important to maintain drugs
within a therapeutic window avoiding high concentrations that may be toxic, while
maintaining concentrations that provide a therapeutic benefit. The LP model is
structured to provide temporal control of flow rate for a delivered compound. To
explore the impact of pulsatile flow on concentration profiles and total drug deliv-

Figure 5.9: Left: Drug concentrations as a function along the length of ST with
both continuous flow (red) and pulsatile flow (blue region shows range). The concentration is taken at 140 min representing the steady state concentration profile.
Total drug delivered is reduced by 75% with the pulsatile delivery approach as compared to continuous infusion. Right: The temporal change in concentration for a 20
minute window centered around 140 minutes. Pulsatile concentrations are shown in
blue (basal) and magenta (apex) while continuous flow are shown in red (basal) and
green (apex). Any concentration within the white region will fall in the notional
therapeutic window.
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ered, a range of on-off times from Ton = 1 min to 10 min and Toff = 1 min to 19 min
at a fixed flow rate of 8 nl/min were evaluated in forward simulations for a basal turn
ST cochleostomy infusion. A notional therapeutic window was arbitrarily defined
between 20% and 80% of the infused drug concentration for illustration purposes.
One result is presented in Fig. 5.9 where the infusion was pulsed on for 1 minute
followed by an off period with zero flow for 3 minutes. The results are compared to
continuous flow at 8 nl/min demonstrating the ability to significantly reduced the
high basal concentrations associated with continuous delivery while minimally impacting apical concentrations. This approach enabled a 75% reduction in total drug
delivered while keeping concentrations within the notional therapeutic window.
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Chapter 6
3D-VSegCaps and Attention
V-Net
One of the important aspects of our dataset is that the ground truths used in training
CNNs are not expert labeled. Referring to Fig. 6.1, although membrane boundaries
between two regions can be visually discerned in the segmentation mask, it is barely
seen in the scan. This restricts manual expert labeling from achieving good quality
labels of the scan. Thus we rely on atlas-based segmentation for ground truth
creation. The ground truths are visually inspected for obvious errors (inclusion
of bones along the boundary edge). In this sense, it can be argued that our VNet is actually learning how to mimic the performance of atlas-based segmentation.
Furthermore, to show the effectiveness of our ground truth creation using atlas-based
segmentation, we used our dataset to train a U-Net 3D and V-Net with attention.
127
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Figure 6.1: Left: 2D slice from µCT image of the left cochlea of a mouse at baseline. Right: corresponding slice of ground truth masks. Boxes show barely visible
membrane between the regions.

6.1

U-Net

As previously mentioned, U-Net was proposed by [57] to perform segmentation of
neuronal structures in EM stacks and cell segmentation in light microscopy images. Segmentation networks with large number of trainable parameters suffer from
vanishing gradients. Vanishing gradients occur when gradients created during backward propagation decrease exponentially in a network with large number of layers.
Without the gradient, the network fails to learn. A key part of U-Net to mitigate
vanishing gradients were the skip connections as seen in Fig. 6.2 between the encoder
and the decoder branches. Similar to residual connections, wherein the connections
”skip” a weight layer, in U-Net the connections skips multiple layers and connect
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Figure 6.2: 3D U-Net architecture. The blue cubes represent n number of channels,
where n is labeled on top of each cube.

the encoder layers to the decoder. Apart from helping with vanishing gradients,
the skip connections pass the features learnt during encoding to aid in any sparsity
created during decoder upsampling.
To compare the performance with V-Net, we implement a 3D version of UNet as established by Cicek et al. [75]. Our implementation as seen in Fig. 6.2,
helps capture the spatial relation in all three dimensions of a 3D modality. The
implementation is straight forward and replaces all 2D operations (convolution, max
pooling, up-conv) to 3D operations.
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6.2

V-Net with Attention

As seen in chapter 5, V-Net performs well on our cochlea dataset. However, in order
to enable better performance on a wider range of medical imaging applications, we
need to further improve performance and generalizability of the network. This lack
of generalizability can be seen in the particularly poor result shown in Fig. 6.3
from the trained V-Net. We can observe that the network recognizes the general
anatomy of the organ, but in some cases, does not match the shape and size of the
scala. Additionally, erroneous blobs are also predicted as part of the segmentation
in rare cases.
One way to improve network performance and generalizability is to include more
convolution layers to enable the network to learn more high level complex features.

Figure 6.3: Scala tympani predicted by our network for one sample scan.
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However, this will increase the number of trainable parameters, in-turn increasing
the need for more data to train the larger network. Acquiring more data still does
not solve the problem of varying shape and scale of different specimen anatomies,
in fact, we can argue that it amplifies the issue due to the inclusion of more data
samples. Another simpler way without increasing network size is to use the attention
mechanism.
The attention mechanism, as the name states, works by focusing on the part of
the image relevant to the task at hand. For example, in the case of the cochlea,
the attention mechanism might force the network to focus on features specifically
related to the scalae rather than pass every feature to the decoder. In segmentation
networks, the attention blocks (usually comprised of a cascade of convolution blocks
and activation functions) are placed in the decoder path at before every up-sampling
block. The idea here as explained above, is to only retain relevant features coming
in from the encoder via the skip connection, and use them to reconstruct the output
segmentation.
Attention itself can be classified into hard and soft attention. Hard attention
is where an algorithm creates either one region of interest each epoch or multiple
regions during the same epoch. Since these regions are independent from each other,
they force the network to either choose them (attention) or not. This makes the
method non-differentiable, making it unusable in segmentation networks that use
differentiable algorithms like back-propagation [97]. On the contrary, soft attention creates a weighting mechanism over the image similar to a heatmap, where
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group of pixels (or voxels) can be weighted based on the amount of influence the
features in the group have on network performance. These attention weighting can
be implemented using convolutional layers, making them differentiable and in-turn
trainable.
Attention has been used increasingly in the medical imaging works in recent
times. Although CNNs learn rich features from the dataset they are trained on,
they fail to separate features based on their importance or relevance on an image
by image basis. In medical imaging, and specifically with our cochlear dataset, the
images are similar in appearance having been acquired from a single source, with
the same imaging parameters, and same orientation in space. This makes having
attention relevant, since it tells the network where to look in an image and assign
higher weight to features that are of significance. Wang X. et al. [98] propose
a variation of attention called Volumetric Attention that concentrates on spatial
information within the slice of the volume as well as from neighboring slices. Chen S.
et al. [99] describe an attention model that works on multiple tasks of segmentation
as well as reconstruction of the positive classes, while Nie D. et al. [100] train
a separate network that predicts a confidence map that acts as attention over a
region. Moreover, the later two works take advantage of attention mechanism to
achieve performance improvement in the semi-supervised learning paradigm.
Adding to the multiple attention mechanisms available, we adopt the Attention
Gate (AG) module, a soft attention mechanism that was introduced by Oktay O.
et al. [101], and applied to U-Net. However, we use the AG module in our V-Net
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Figure 6.4: V-Net with AG module

architecture, and to the best of our knowledge is the first application of attention
mechanism on V-Net.
Our V-Net architecture with AG module is shown in Fig. 6.4. Attention module
is included in the decoder part of the network between the first three blocks starting
from the bottleneck block (block 5). This enables the AG module to collect inputs
from both the previous decoder block, as well as the skip connection.
The AG module is shown in Fig. 6.5 with inputs g from the previous decoder
block and xl from the skip connection. Within the AG module, to equalize the
number of channels in the gating signal g and xl , they are passed through two
different 1 × 1 × 1 convolutions. The 1 × 1 × 1 kernel size maintains the respective
spatial size of the inputs. In order to continue to the next addition operation, the
spatial size of xl is equalized to that of g by passing it through an up-sampling
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Figure 6.5: Attention Gate module

operation. The output of the addition operation is then passed through ReLU
activation. The attention map in the final step is obtained by sending the ReLU
activations through another 1 × 1 × 1 convolution followed by sigmoid activation.
The convolution operation in this case brings the channel count down to 1, whereas
the sigmoid forces the values of the channel between 0 and 1. This final channel
represents the attention map that is finally resampled and multiplied with skip
connection inputs. This final multiplication operation is what makes the attention
map pick relevant features from the skip input.

6.3

Capsules for Segmentation

As a final step in using CNNs to segment 3D images, we explore the paradigm
of capsule networks that can be applied to segmentation task. Capsule networks
contain fewer parameters compared to their equivalent U-Net or V-Net and can
generalize better and learn robust features from the images. This sets up networks
to extend the current work in the future to bigger datasets and include even complex
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shaped anatomies as part of the datasets.
Capsule networks address some of the drawbacks of CNNs like size and orientation of the images. CNNs tend to learn features statistically, but fail to learn where
to place those features in the image. For example, a network trained to recognize
features on a face, will fail to place parts of the face (nose, eyes, mouth) in the
right location if the face is zoomed in and oriented in a way that’s not seen in the
data distribution. So capsule networks can be said to learn the part-whole relationships of the image. Additionally capsule networks replace max-pooling which
is a major source of information loss in CNNs, with strided convolutions. It also
employs dynamic routing, which is an algorithm that connects only those features
from a previous layers to similar features in the next layer, thus maintaining a ’route’
from input to output. The first such capsule network (CapsNet) was introduced by
Sabour S. et al. [102] for digit classification. They introduced the concept of capsules, which are essentially a representation of inputs as vectors, whereas ’neurons’
in CNNs use scalars to represent the inputs. They achieved a test error of 0.25%
from CapsNet that has only 8.2M parameters. In comparison, a CNN with 36.5M
parameters can achieve similar level of performance. LaLonde et al. [103] introduced
capsule network for 2D segmentation called SegCaps that implement convolutionaldeconvolutional capsules and locally-constrained routing. The original capsules are
computationally expensive due to their routing mechanism that maintains the relation between all the layers. In SegCaps, convolutional capsules leverage the power of
extremely efficient CNN frameworks for fast computations on the GPU. Moreover,
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Figure 6.6: 3D SegCaps: 3D Segmentation Capsule network

the locally constrained routing restricts the routing to layers that fall within a local spatial-kernel. These two methods enable construction of encoder-decoder style
SegCaps using convolutional capsules. Nguyen et al. [104] extended 2D SegCaps to
design 3D-UCaps based on the U-Net. Their 3D-UCaps achieves better performance
than 3D U-net on multiple datasets proving the efficacy of convolutional capsules.
Improving on the 2D SegCaps, we propose 3D-SegCaps that include 3D to include
3D convolutions and design the routing algorithm to apply the constraints in 3D
local kernel. So the spatial features across slices are also routed to consecutive
convolutional capsule layers. Fig. 6.6 shows our 3D-SegCaps network. Moreover,
we go a step further to include residual connections similar to that in a V-Net and
design 3D-VSegCaps as shown in Fig. 6.7. This to the best of our knowledge is the
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Figure 6.7: 3D-VSegCaps: 3D SegCaps Network with Residual connections in each
block.

first implementation of a V-Net like network using convolutional capsules. The 3DVSegCaps includes a residual connection at each encoder and decoder capsule blocks
similar to V-Net. The same routing algorithm explained briefly in the subsection
6.3 is used in both networks.

Routing algorithm
A local kernel kh × kw × kd is centered at a position (x, y) in any layer, and weights
between all capsules within this kernel and another capsule in the consecutive layer
are initialized to 0. First step in the algorithm is to obtain the softmax of these
weights. The inputs to the capsules in the consecutive layer is the weighted sum
of all prediction vectors from capsules in previous layer multiplied by the softmax
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calculated in the previous step to update these prediction vectors by the weights.
Next step, called ”squashing” is a key step in the routing algorithm that introduces
non-linearity. The updated prediction vectors are passed through the squashing
function defined in Eq. 6.1.

pnew

pxy
||pxy ||2
=
1 + ||pxy ||2 ||pxy ||

(6.1)

where p are the old prediction vectors. The new prediction vectors are multiplied
with the old prediction vectors and the product is added to weights initialized. This
algorithm is repeated for n iterations (usually 1 or 3), and the new prediction vectors
are returned at the end of the iterations.

Since the original SegCaps work tested their network on the LUNA dataset, we
decide to test our 3D-SegCaps and 3D-VSegCaps on the same dataset given its large
dataset size.

Figure 6.8: Network to reconstruct the positive class from 3D-VSegCaps output
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CNN based networks
We test the performance of U-Net, V-Net, and V-Net with attention on LUNA
[105] - lung segmentation CT dataset, Promise 2012 [106] - prostate segmentation
in T2 weighted MRI dataset, a sample of both can be seen in Fig. 6.9, and our
Cochlea dataset. Adding to the dice loss used to train V-Net in chapter 5, we use a
combination of binary cross entropy (BCE) loss for class discrimination, and mean
square error (MSE) loss for reconstruction of the positive class along with dice loss
for class imbalance issues.

Figure 6.9: Left: Sample showing both lungs in a chest CT from LUNA dataset.
Right: Sample showing prostate in a pelvic MRI from Promise2012 dataset
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Table 6.1: Performance metrics for U-Net, V-Net and V-Net with attention for
LUNA, Promise 2012 and Cochlea datasets
Datasets
LUNA
Promise 2012
Cochlea

Avg. Jaccard Index
U-Net
V-Net V-Net+AG
97.44% 93.48%
95.4%
78.06% 82.48%
83.21%
89.53% 89.95%
90.19%

It can be seen from Table 6.1 that there is no significant performance improvement seen from U-Net for LUNA dataset. Given the larger dataset size (887 images)
and more importantly the large simpler shape of the segment, the core network itself
might have captured most of the discriminative features, leaving very less for the
attention mechanism to improve on. However, for both Promise 2012 (50 images)
and Cochlea (137 images) dataset, the number of training samples themselves are
significantly lesser compared to LUNA, and the shape in case of cochlea dataset is
fairly complex as well. They rely on data augmentation to achieve the performance
shown above and can be improved with techniques like attention in this case. Moreover, due to multiple loss function used to train the network, we see improvement
from results in chapter 5.

Capsule based networks
Training the 3D-SegCaps and 3D-VSegCaps were carried out using equally weighted
sum of BCE, MSE and dice loss functions. The network is regularized by recon-
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Table 6.2: Performance metrics for SegCaps, 3D-SegCaps, 3D-VSegCaps for LUNA
dataset
Datasets
LUNA

Avg. Jaccard Index
SegCaps 3D-SegCaps 3D-VSegCaps
93.25%
93.87%
95.42%

structing the positive class by passing only predicted positive class part from the
output of the network through another small convolutional reconstruction network
shown in Fig. 6.8. The learning rate was initially set to 0.00005 and annealed at a
rate of 10% every 5 epochs for the first 20 epochs, and then at a rate of 50% every
5 epochs further on. Although the original work and U-Net both had batch size of
1 for training, we noticed in our experiments that our implementations performed
better with a batch size of 2. The network were trained for 200 epochs or 62,000
iterations, and we did not notice any overfitting towards the end of training. The
IOU for LUNA dataset is tabulated in Table 6.2.
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Chapter 7
Conclusion
In this work, we constructed a pharmacokinetic model of cochlear compartments
of the mouse using micro computed tomography images. This was enabled by the
extraction of cochlea region of interest from the full head scan of the mouse, followed
by the segmentation of scala tympani, scala media and scala vestibuli from the
cochlea. µCT imaging was successfully performed on the mouse with continuous
infusion of an iodine based contrast agent a seen in chapter 2. The surgical and
imaging procedure was further validated by multiple successful experiments showing
good concentration at the base of scala tympani through time. The concentration
of the contrast agent in each scalae were extracted along the central axis of each
scala, and the concentration profile shows expected infused concentration at the base
of ST with a slow diffusion towards the apex. The separation of these individual
compartments was achieved by atlas-based segmentation, where compartments were
143
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segmented by deforming a pre-defined atlas to our scans as shown in chapter 3. The
pharmacokinetic model constructed using these extracted concentrations, produces
simulations that showcase similar basal concentrations in ST with a diffusion towards
apex, given the same experimental initial conditions. The transfer parameters and
simulated profiles are comparable to those obtained from existing pharmacokinetic
models such as FluidSim. As seen in chapter 5, this novel pipeline demonstrates
the ability to non-invasively measure the concentration within a mouse cochlea and
simulate concentration profiles for any solute within ST, SM and SV given various
initial conditions.
On the other hand, we trained a V-Net, a encoder-decoder style convolutional
neural network, to predict the voxels related to the scalae instead of directly deforming a template (atlas). This methods achieves faster computational time compared
to the former, while maintaining the anatomy of the scalae. Segmentation results
from both methods are similar with the the distance between both medial axes being
less than 7% of the entire axis length. We can see these results in chapter 4. Moreover, the extracted concentrations show that both these methods result in similar
concentration profiles and the error plots provide a quantitative proof of the similarity. To further decrease computation speed and overhead, we explored capsule
networks for segmentation in chapter 6. Results show that 3D-VSegCaps designed
as part of this work, can achieve better performance compared to our modified VNet. Moreover, capsule networks have almost 80% less parameters resulting in less
computational overhead, making them scalable to large datasets. While this work
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sets up the necessary algorithms to extract concentration and build a pharmacokinetic model, it can be further validated by scaling the experiments to larger rodents
such as guinea pig that have even complex cochlear structures.

7.1

Future Work

This thesis has setup the platform for potential future exploration on multiple topics. To start with, the pharmacokinetic model can be extended to larger rodents
and animal experimentation can be performed to prove the efficacy of the model.
A key limitation of the presented work is that the molecules which can be quantified are limited to those exhibiting image contrast for µCT imaging as we discussed
in 5.5. There are no known equations to enable direct incorporation of molecule
properties like lipophilicity and TPSA into the K values. One approach to advance intracochlear pharmacokinetic models would be to leverage the µCT imaging techniques presented herein, with a range of triiodo compounds that span the
lipophilicity/TPSA space. These parameters can be incorporated into the learning
paradigm to provide advanced transport parameters for forward model simulations,
where molecular characteristics are directly entered for an arbitrary compound. The
pharmacokinetic model itself can be improved by using complex methods such as
adjoint methods for solving partial differential equations in constrained optimization
problems. Furthermore, the segmented compartments can be modeled using finite
element methods to obtain actual shape information of the compartments. Instead
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of modeling a simple tube with varying cross-sectional area, we can use the actual
shape information of the compartments obtained from the finite element analysis
step.
On the other hand, a new paradigm of neural networks called transformers are
quickly replacing CNNs because of their ability to apply self-attention. Given more
data obtained from further animal experiments, a larger dataset can train a transformer network to give better performance. Moreover, an end-to-end solution can
be explored by concatenating multiple networks that work together to segment and
predict the concentration together.
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